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Chapter 1 
Introduction 
1.1 The tumorigenesis 
Most tumors do not result from a single phenomenon, hence tumorigenesis is a 
complex and multifactorial process characterized by the acquisition of several 
abnormal functionalities, needed by the cells to evolve through different 
premalignant steps into invasive cancers. So, they originate from normal cells that 
have experienced a transformation process as a result of mutations induced by errors 
in cell replication or by exogenous factors, as X-rays, UV light, chemicals and 
oncoviruses (Figure 1.1). 
 
Figure 1.1: The transformation process of normal cells into malignant ones. The picture is a 
modification of that reported in literature [1]. 
These alterations confer to mutant cells a selective growth advantage, allowing them 
to proliferate out of control. This process, called evolutionary clonal selection, makes 
the cell to acquire malignant traits, which are the hallmarks of tumor [1]. The normal 
cell that acquire the initial cancer-promoting mutation is considered the “cell of 
origin”. On the contrary, the subset of self-renewing cancer cells that uniquely 
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sustain tumor malignant growth are known as cancer stem cells (CSC). These cells 
have proven to be a common component in most tumors and several hypotheses have 
been proposed about the origin of CSC, either from stem or differentiated cells; 
however, until now little is known about them [2]. 
Tumorigenesis is the result of mutations in protein-encoding genes, which can be 
classified into two classes: proto-oncogenes and tumor suppressor genes. Proto-
oncogenes encode for proteins which promote cell growth and proliferation, 
including kinases, tyrosine kinase receptors, transcription and growth factors and 
GTPase regulators. Their mutated form are known as oncogenes. A representative 
example is the RAS protein family, chronically active in 30% of cancers, due to 
inactivating mutations in one of its negative regulators or missense mutations in its 
gene. The components of downstream cascades mediating RAS functions could be 
mutated in similar way in different type of cancers. Thus, mutations in RAS, in its 
regulatory proteins and in its downstream pathways result in a panel of effects which 
enhance growth and proliferation [3]. On the other hand, tumor suppressor genes  
encode for proteins which operate in different ways in order to limit cell growth and 
proliferation. The most commonly mutated (in over 50% of sequenced malignancies) 
tumor suppressor gene encodes for P53. This protein acts as a detector of a variety 
of stresses, arresting further progression of cell cycle, being involved in repair 
mechanism, or eventually triggering apoptosis if the degree of damage is excessive 
[4]. Another key tumor suppressor gene encodes for retinoblastoma (RB) protein, 
which is commonly inactivated in a great number of cancers. It is a critical regulator 
of cell-cycle progression and its absence leads to persistent cell proliferation [5]. 
Thus, mutations, which affect both oncogenes and tumor suppressor genes, cause 
uncontrolled cell proliferation and, consequently, alterations in tissue homeostasis. 
Despite cancer is not a single disease, but exhibit a strong heterogeneity in cellular 
morphology, proliferative activity, genetic lesions and response to therapy, generally 
malignant cells show the following features: 
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• selective growth and proliferative advantage, due to self-sufficiency in 
growth signals and insensitivity to antigrowth pathways; 
• altered stress response leading to overall cell survival, for example defects in 
DNA repair machinery, escape of cell death (both apoptosis and autophagy) 
and loss of senescence ability; 
• sustained angiogenesis and other modes of tumor neo-vascularization; 
• acquisition of the capacity to invade surrounding tissue and to form 
secondary sites of growth (metastasis); 
• metabolic rewiring that represents a selective advantage during initiation and 
progression of cancer, as the switch from aerobic to anaerobic metabolism, 
phenomenon known as “Warburg effect”; 
• creation of dynamic and rich microenvironment; 
• ability to escape immune surveillance, supported by the fact that primary and 
acquired immunodeficiency in mice and humans are related with greater 
susceptibility to carcinogenesis [1]. 
1.2 Cell cycle 
Cellular replication is regulated by the cell cycle, a tightly ruled process with 
multifactorial and very complex control mechanisms. It is divided into several 
stages, each of them with very typical functional properties. Upon receiving the 
mitogenic stimulus the eukaryotic cell starts its cell cycle in G1 (gap 1) phase: the 
cell shows a rise in the expression of protein and in its metabolism, in order to set 
the conditions needed for the following S (synthesis) phase, which is the step 
involving DNA replication. This is followed by the G2 (gap 2) phase, during which 
the accuracy of chromosome replication is checked and further synthesis of the 
proteins occurs. G1, S, and G2 form the interphase. Then, the M (mitotic) phase is 
characterized by the separation of chromosomes in the nucleus and, finally, by the 
division of cytoplasm, called cytokinesis (Figure 1.2). 
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Figure 1.2: The cell cycle events. The picture is a modification of that reported in literature [6]. 
After M phase, cells can enter into a new G1 phase or proceed to a quiescent state, 
known as G0, which can persist for a long time, or even for the rest of cell life in the 
case of some somatic cells. The strictly correlation between a step and the correct 
completion of the preceding one allows the successful progression of cell cycle. The 
interdependency is related to surveillance mechanisms, namely checkpoints, which 
prevent the propagation of genetic abnormalities. If cell damage cannot be repaired, 
checkpoint signaling may induce apoptosis. This control system is based on two 
groups of proteins: the family of cyclin-dependent kinases (CdKs) and cyclins. CdKs 
bind cyclins and check their ability to phosphorylate appropriate targets. There are 
several classes of CdKs and cyclins, depending on the step of the cell cycle where 
they are activated (Table 1). 
Loss of cell cycle regulation leads to uncontrolled cell proliferation, which is an 
hallmark of cancer [7]. 
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CYCLIN-CDK 
COMPLEX 
VERTEBRATES 
   CYCLIN             CDK PARTNER 
BUDDING YEAST 
CYCLIN               CDK PARTNER 
G1-Cdk 
G1/S-Cdk 
S-Cdk 
M-Cdk 
 
   cyclin D*          Cdk4, CdK6          
   cyclin E            Cdk2 
   cyclin A            Cdk2, Cdk1**       
   cyclin B            Cdk1 
Cln 3                    Cdk1** 
Cln1, 2                 Cdk1 
Clb5, 6                 Cdk1 
Clb1, 2, 3, 4        Cdk1 
Table 1: The main classes of cyclins and CdKs, referred to vertebrate and budding yeast [6]. 
1.3 Cell death 
Like cell growth and proliferation, cell death plays a crucial role in tissue 
homeostasis. Defects in the regulation of cell death are related to a variety of human 
disease, including tumor. In addition, the main purpose of anticancer drugs is 
selectively inducing cell death in malignant cells only. Different kinds of cell death 
can be distinguished, according to biochemical and morphological parameters, but 
they are strictly interconnected and may co-exist, hence often it is difficult to 
discriminate them [8]. 
1.3.1 Apoptosis 
Apoptosis is a type of programmed cell death and it is a key component of cell 
growth control. It is fundamental for various processes involved in tissue 
homeostasis, as embryonic development and organogenesis. Thus, abnormal 
regulation of apoptosis leads to pathogenesis of several human disorders, particularly 
its suppression is strictly related to tumorigenesis. 
This kind of cell death is characterized by a series of morphological changes, such 
as cell shrinkage and reduction of cell volume (pyknosis), disruption of organelles 
membrane, chromatin condensation, nuclear cleavage (karyorhexis) and finally cell 
fragmentation into apoptotic bodies, which can be engulfed by macrophages. 
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Apoptosis may be triggered by a plethora of signals and it is induced by two major 
pathways: the intrinsic and extrinsic one (Figure 1.3). Both pathways converge in the 
activation of a specific series of cysteine aspartyl-protease, known as caspases, 
which are both the initiators (like caspase 2, -8 , -9 and -10), showing autocatalytic 
activity, and the downstream effectors (as caspase 3, -6 and -7), activated by 
proteolytic cleavage by the previous ones. The effector caspases can further cleave 
other nuclear and cytosolic substrates, progressively activating proteolytic cascades 
that lead to the biochemical and morphological features of apoptosis.  
The intrinsic apoptotic pathway is triggered by intracellular signals, such as DNA 
damage. Upon these stimuli the activation of pro-apoptotic proteins, as BAX, BAK, 
BAD and BID, leads to mitochondrial outer membrane permeabilization (MOMP), 
resulting in the release of proteins from the mitochondrial intermembrane space. 
Among them cytochrome c is the most important; indeed, once released in 
cytoplasm, it transiently binds the apoptotic protease-activating factor 1 (Apaf-1), 
triggering Apaf-1 oligomerization into an heptamer, which exposes the caspase 
activation and recruitment domain (CARD). This domain binds to pro-caspase 9, 
forming a multi-protein complex, namely apoptosome, in which pro-caspase 9 auto-
activates and subsequently recruits the executioner caspases 3 and -7 to orchestrate 
apoptosis. This pathway can also be modulate by anti-apoptotic proteins (e.g BCL-2 
and IAPs). 
On the contrary, the extrinsic pathway is activated by cell transmembrane receptors 
in the presence of extracellular signals. These death receptors include a subset of 
tumor necrosis factor (TNF) superfamily, characterized by different protein motifs, 
called death domains (DD) and death effectors domains (DED). There are three main 
receptor-systems involved in this apoptotic pathway: Fas, activated by Fas ligand 
(Fas L); tumor necrosis factor receptor 1 (TNFR1), activated by tumor necrosis factor 
a (TNF-a); and death receptors 4 and 5 (DR4, DR5), activated by TNF-related 
apoptosis inducing ligand (TRAIL). After the activation, these receptors attract DD-
containing molecules, such as Fas-associated death domain protein (FADD), thus 
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triggering pro-apoptotic pathways. FADD recruits other DD/DED-containing 
factors, including pro-caspases 8 and -10, promoting the formation of the death 
inducing complex (DISC) in the cytoplasm. The recruitment of these proteins in 
DISC favors their self-cleavage and once activated, caspases 8 and -10 directly 
engage the effector caspases 3, -6 and -7 to perpetrate apoptotic cell death. 
Alternatively, caspase 8 can activate BID, promoting the intrinsic apoptotic pathway 
[9] [10]. 
 
Figure 1.3: Key step in apoptotic intrinsic and extrinsic signaling pathways. The picture is a 
modification of that reported in literature [11]. 
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1.3.2 Autophagy 
Autophagy is another type of programmed cell death. It contributes to cell 
homeostasis by degrading several intracellular materials, particularly dysfunctional 
organelles, protein aggregates, and invading pathogens. Similarly to apoptosis, 
aberrant autophagy seems to be linked to a wide range of human diseases, including 
cancer. It has been reported that autophagy plays contradictory roles in tumor 
initiation and progression. Hence, both stimulation and repression of autophagy 
should be explored as therapeutic approaches, due to the several factors that 
contribute to tumorigenesis. 
The general term autophagy describes the process by which cytoplasmic components 
are delivered to lysosomes for degradation. Three main autophagy pathways have 
been elucidated, which may be distinguished by the delivery method of substrates: 
macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) [12] 
(Figure 1.4). 
 
Figure 1.4: Three main autophagic pathways. The picture is a modification of that reported in 
literature [13]. 
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Among the three autophagic pathways, macroautophagy represents the main and the 
most studied one. During this process, an isolation membrane, called phagophore, 
encloses a small part of unnecessary or dysfunctional cytoplasmic components, such 
as damaged organelles, forming a double-membraned structure, namely 
autophagosome. Then, its outer membrane fuses with lysosomes, to evolve into an 
autolysosome, in which lysosomal enzymes degrade the cytoplasmic substrates 
(Figure 1.4). Macroautophagy consists of different steps: initiation and nucleation, 
elongation, maturation, fusion and degradation (Figure 1.5). The machinery is finely 
regulated by a series of factors, the Atg proteins, which can assemble into many 
different multimolecular complexes to form autophagosome. Among them, the Unc-
51 like kinase 1 (ULK1) complex plays a key role in the initiation of the process. In 
fact, in response to several stresses, like starvation, the serine-threonine kinase 
mammalian target of rapamycin (mTOR) is inhibited and dissociates from the ULK1 
complex, leading to its activation and to the initiation. The activation of this complex 
promotes the recruitment of the class III phosphatidylinositol 3 kinase (PI3K), which 
is essential for the nucleation and assembly of phagophore membrane, through the 
phosphorylation of key factors, like activating molecule in Beclin-1-regulated 
protein autophagy 1 (AMBRA) and Beclin-1. The subsequent elongation process 
involves two conjugation reactions leading to Atg5-Atg12 and microtubule 
associated protein-1 light chain (LC3)-phosphatidylethanolamine (PE). The product 
of the second conjugation is essential for the closure of the autophagosome 
membrane. Finally, in the fusion stage, in which autophagosome fuses with lysosome 
to form an autolysosome, are involved monomeric GTPases of the Rab family. This 
process is followed by the lysosomal degradation of the autophagic substrate [9]. 
 
 
  10 
 
 
 Figure 1.5: The macroautophagy steps. The picture is a modification of that reported in 
literature [14]. 
Conversely, microautophagy is the less studied. It is characterized by the direct 
engulfment of cytoplasmic portions by the lysosomes (Figure 1.4). Thus, the 
lysosomal membrane randomly undergoes invagination and differentiation into 
autophagic tubes, in order to enclose substrates for degradation. The main functions 
of microautophagy are the maintenance of membrane homeostasis, organellar sizes, 
and cell survival under nitrogen starvation [15]. 
The third type of autophagy, CMA, is a process in which the substrates are proteins 
containing a specific pentapeptide motif which are selectively recognized by a 
chaperone protein, belonging to the family of Heat Shock Proteins 70 (HSP70), the 
HSPA8/HSP70. The resulting chaperone-substrate complex binds the lysosomal 
receptor lysosomal-associated membrane protein type 2A (LAMP-2A), leading to its 
multimerization, with the help of the lysosomal protein HSP90. Then, the substrates 
are unfolded and delivered to the lysosome lumen, through the LAMP-2A-enriched 
translocation complex, where lysosomal proteases degrade them (Figure 1.4). 
Subsequently, LAMP-2A multimers undergo disassembly and degradation for the 
next cycle of CMA. This pathway is tightly regulated and can be activated under 
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protracted starvation and a variety of stresses, and it represents a quality control 
aimed to remove unfolded or damage proteins [16]. 
1.3.3 Necrosis 
Necrosis is another type of cell death without the typical features of apoptosis (cell 
shrinkage, pyknosis, karyorhexis and formation of apoptotic bodies) and without 
abundant autophagic vacuolization. On the contrary, the main characteristics of 
necrosis include an increase of cell volume (oncosis), which finally leads to a 
disruption of plasma membrane and to disorganized dismantling of swollen 
organelles. Thus, this type of cell death lacks typical biomarkers, except for the 
plasma membrane permeabilization. Necrosis is usually regarded as harmful, due to 
its association with pathological cell loss and to the capacity of necrotic cells to favor 
local inflammation, which can support tumor growth [17]. 
1.3.4 Non-lethal processes: cell senescence and mitotic 
catastrophe 
The molecular machinery involved in cell death is also related to other processes that 
cannot be considered as cell death per se, including cell senescence and mitotic 
catastrophe. 
Cell senescence is a pathophysiological state during which the cells persistently lose 
their proliferative ability  while remaining metabolically active and viable. Senescent 
cells show typical morphological features, such as intracellular vacuolization, altered 
chromatin structure, flattening and cellular or nuclear enlargement. The biochemical 
markers are: increased lysosomal galactosidase beta (GLB1) activity, inhibition of 
several CDKs and subsequent dephosphorylation of multiple members of the RB 
protein family, absence of proliferation markers, activation of the DNA damage 
response (DDR) machinery, and presence of senescent-associated heterochromatic 
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foci (SAHF). Moreover, senescent cells secrete the so-called senescent-associated 
secretory phenotype (SAPS), composed by mitogenic and immunomodulatory 
chemokines, cytokines and growth factors, which is involved in the immunological 
clearance of these cells, and also modulate the activity of other cells with an intact 
proliferative capacity. Hence, cell senescence seems to contribute to embryogenesis, 
as well as to several adult pathophysiological processes, such as tissue regeneration 
and repair, immunity and tumor suppression. Particularly, cell senescence has been 
reported to occur in response to potentially tumorigenic events (as tumor suppressor 
genes inactivation or oncogenes activation) and various sublethal cell insults 
(including DNA damage, telomere shortening, mitochondrial dysfunctions). 
However senescent cells are also implicated in the side effects of some 
chemotherapeutic treatments and in the recurrence of specific cancers, thus 
senescence plays a controversial role in cancer progression, acting both as a tumor 
suppressor and promoter. 
Mitotic catastrophe is a regulated mechanism, hampering the proliferation and the 
survival of cells that cannot complete mitosis, due to extensive DNA damage, defects 
in the mitotic machinery and failure of cell cycle checkpoints. Mitotic defects can 
originate both from exogenous and endogenous sources, and the main alterations 
driving aberrant mitosis can derive from other cell cycle phases, especially the S 
phase. This process is morphologically characterized by typical nuclear alterations, 
as multinucleation, macro- and micronucleation, while the molecular mechanisms 
triggering mitotic catastrophe cascade are still unclear, but probably involve p53 in 
many cell types. The destiny of cells undergoing mitotic catastrophe appears to be 
related to the period spent under mitotic arrest, and their ability to escape from 
abnormal mitosis. Hence, the arrested cells may undergo cell death (most often 
intrinsic apoptosis) or enter cell senescence, after activating some cell cycle 
checkpoints. Consequently, the abrogation of mitotic catastrophe constitutes a 
fundamental event during tumorigenic transformation and progression [8] [17]. 
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1.4 The anticancer chemotherapy 
The oldest case of cancer was described around 3000 BC in an Egyptian papyrus, in 
which eight cases of breast tumors were recorded along with their treatment by 
cauterization. Thus, surgical resections were historically the main way of  cancer 
treatment. Later, in 1896 X-rays began to be used for recurrent breast carcinoma 
therapy, and since then radiotherapy and surgery represented the main treatments. 
Only since 1950 chemotherapy has become a valid therapeutic option, with the 
discovery of nitrogen mustard (now regarded as the first chemotherapeutic agent) 
and its application for lymphomas and solid tumors therapy. This event led to a rapid 
development of various chemotherapeutics. However, despite the advances in this 
field, nowadays cancer remains one of the major cause of death worldwide, partly 
due to an ageing global population [18]. 
The ultimate goal of conventional anticancer chemotherapeutics is to induce 
malignant cells to die or arrest their proliferation. Hence, they mainly modify, 
directly or indirectly, the cell cycle. Anticancer agents may act as cytostatic or 
cytotoxic drugs. Cytostatic drugs stop the cancer cells proliferation, by inhibiting 
signaling pathways related to processes as cancer growth, angiogenesis, invasion and 
metastasis. For example the current therapies include: receptor antagonists, 
antigrowth factors antibodies, small tyrosine kinase inhibitors and anti-receptor 
monoclonal antibodies [19]. 
Conversely, cytotoxic agents target rapidly proliferating cells, as cancer cells, 
leading to cell death. These represent most of anticancer drugs and, according to their 
main mechanism of action, they can be divided into: 
• alkylating agents, which react with DNA, chemically modifying its structure; 
• antimetabolites, which inhibits DNA and RNA synthesis; 
• topoisomerase inhibitors, which interfere with the correct DNA unwinding 
during replication and transcription; 
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• microtubular poisons, which hamper the polymerization and 
depolymerization of tubulin, thus inhibiting mitosis; 
• cytotoxic antibiotics, which exert anticancer effects by several mechanisms, 
such as DNA intercalation and over production of reactive oxygen species 
(ROS) [20]. 
Nowadays, immunostimulating- and targeted-therapies are considered among the 
most promising strategies to get high therapeutic antitumor effects with mild 
systemic toxicity. However, traditional chemotherapy is still one of the treatments of 
choice for several highly aggressive cancers. Most of such chemotherapeutic 
schedules consist of the so-called combination therapy (i.e. the administration of two 
or more additive, or better synergistic, drugs together). In order to improve patient 
compliance, the different drugs are usually incorporated into the same formulation. 
However, this is not a simple task because of pharmacokinetic differences between 
drugs; moreover, possible interactions between the individual components can occur. 
Thus, a more effective strategy to reach such a goal may involve the preparation of 
a single drug containing different agents, reversibly bonded, also called “combo” 
[21]. 
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1.5 Platinum-based anticancer drugs 
1.5.1 History of cisplatin 
Cisplatin, cis-diamminedichloridoplatinum(II), is a square-planar complex of Pt(II) 
coordinated to two chloride ligands (leaving groups) and two ammine ligands 
(carrier groups). The prefix cis indicate the geometry of this complex, where two 
identical ligands are on the same side with respect to the metal, differentiating this 
from its trans isomer (Figure 1.6). 
 
 
 
Figure 1.6: Geometric isomers of diamminedichloridoplatinum(II). a) Cisplatin and b) 
Transplatin. 
Cisplatin was synthesized for the first time in 1845 by Michele Peyrone, and, 
therefore, it was known as Peyrone’s chloride since the end of the nineteenth century. 
Then Alfred Werner elucidated its chemical structure for the first time in 1893. 
However, its anticancer properties were serendipitously discovered in 1965 by the 
physicist Barnett Rosenberg at the Michigan State University, during the 
investigation of the role of electric or magnetic field in Escherichia Coli cell division. 
He observed an inhibition of cell division, not due to the electric field, but to the 
complexes produced by the electrolysis from the platinum electrodes in contact with 
a growth medium containing ammonium chloride. Among the possible species, the 
cis-isomer of [PtIICl2(NH3)2], i.e cisplatin, was identified as the major bioactive 
species. The results suggested that, since this molecule was able to stop bacterial cell 
growth, it might be active also against proliferation of cancer cells. As a result, in 
1968 cisplatin showed the ability to cause a strong tumor regression when 
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administered intraperitoneally to mice bearing sarcoma-180 [22] [23]. After further 
in vivo tests, this compound entered clinical trials and the first patient was treated in 
1971. However cisplatin was approved by the Food and Drug Administration (FDA) 
as anticancer agents in 1978. Since then, cisplatin was employed for the treatment of 
a wide range of solid tumors, including bladder, head and neck, lung, ovarian and 
testicular cancers (in this case cure rates have overcome 95%) [24]. 
The trans isomer is much less active than the cis homologue and so it is not used as 
an anticancer agent. 
1.5.2 Cisplatin mechanism of action 
Cisplatin is administered to patients by intravenous infusion over a period of six to 
eight hours. In the bloodstream the compound does not undergo appreciable aquation 
reaction (hydrolysis) due to the high concentration of chloride ions (about 100 mM), 
although cisplatin can react with plasmatic proteins, as human serum albumin, and 
extracellular enzymes. 
The molecular mechanism by which cisplatin enters cells is not completely clarified 
yet. Being a neutral molecule with moderate molecular weight, cisplatin can cross 
the cell membrane by passive diffusion, although active transporters, like copper 
transporter-1 (Ctr1), and organic cationic transporters (OCT), are also involved in 
cisplatin uptake [25] [26]. 
Once inside the cytoplasm, where the concentration of chloride ions drops to 2-10 
mM, cisplatin undergoes aquation reaction with the replacement of one (monoaqua 
species) or two (diaqua species) chlorido groups with water molecules. The rate of 
the aquation of the first chloride ion at 37°C is 7 x 10-3 min-1 (half-life time is about 
120 min) while the substitution of the second chloride ligand is two times slower 
[27]. 
Once inside the cell, cisplatin interacts with different biomolecules but its main 
pharmacological target is the DNA. The mono- and di-aqua species, positively 
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charged, represent the active forms of the complex and covalently bind to 
nucleophilic sites on the DNA strand. In particular platinum binds nitrogen in 
position 7 (N7) of the imidazole ring of the purine bases, preferentially guanine (G) 
and, to a lesser extent, adenine (A). Cisplatin is able to form monofunctional or 
bifunctional adducts. The most frequent lesions occur on the same DNA strand and 
are known as intrastrand adducts, involving adjacent bases as GpG 1,2 intrastrand 
(60-65% of DNA binding) and ApG 1,2 intrastrand (20-25%). Other binding modes, 
produced on the same strand, includes GpXpG 1,3 intrastrand crosslink, involving a 
third nucleotide X between the two platinated guanines (2%) and monofunctional 
adducts on guanines (2%). Finally, approximately 2% of adducts occur on opposite 
DNA strand (G-G “interstrand crosslinks”). These adducts cause severe distortions 
in the structure of the DNA, including unwinding and bending, thus preventing DNA 
replication and transcription [28] (Figure 1.7). 
 
Figure 1.7: Formation and effects of cisplatin-DNA adducts. The picture is a modification of 
that reported in literature [29]. 
 
Cisplatin-induced DNA damage leads to cell cycle arrest in G2 phase and activation 
of DNA repair pathways, as nucleotide excision repair (NER), mismatch repair 
(MMR) and DNA-dependent protein kinase (DNA PK). Among these, NER is the 
main system known to remove cisplatin lesions from DNA and it is involved in repair 
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of intrastrand Pt-DNA crosslinks. Also the high-mobility group (HMG) proteins, a 
family of  non-histone chromatin-associated proteins, are able to identify and bind 
Pt-DNA adducts, particularly 1-2 intrastrand crosslinks, but these elements have a 
controversial role. Indeed, on the one hand they are implicated in repair efforts, but 
on the other hand they may interfere with the activity of DNA repair enzyme, 
allowing the damage to persist. 
The failure of the DNA-repair ability of the cells and the consequently persistence 
of DNA-adducts activate cell death pathways. Especially, cells treated with high 
concentrations of the drug show a necrotic-like phenotype, while an apoptotic one 
occurs after exposition to (and the pharmacologically optimal) lower concentrations. 
Cisplatin-induced DNA damage activates several proteins, including ATM and ATR 
sensor kinases, p21 and p53, leading to intrinsic apoptosis. Also the extrinsic 
apoptotic pathway may be activated [30]. 
Cisplatin also stresses different cellular organelles, including mitochondria, 
endoplasmic reticulum (ER) and lysosomes. In addition to genomic DNA, the 
platinum complex can bind mitochondrial DNA (mtDNA) with high efficiency, 
inducing characteristic mitochondrial alterations which lead to the activation of the 
intrinsic apoptotic pathway, due to the low efficiency of mtDNA repair. Moreover, 
the drug causes calcium-dependent mitochondrial swelling and depolarization, 
calcium release and decrease in NAD(P)H levels [31]. The mitochondrial 
permeabilization is also linked to ROS overproduction; at the same time cisplatin 
inhibits antioxidant enzymes, such as catalase, superoxide dismutase (SOD), 
glutathione peroxidase, glutathione S-transferase and glutathione reductase, leading 
to mitochondrial and cellular oxidative stress. 
Furthermore, cisplatin induces the activation of ER stress pathways, due to 
deregulation of calcium homeostasis and accumulation of misfolded protein, which 
may lead to apoptosis [30]. Lysosomal alterations and injuries are also involved in 
cell death; cisplatin treatment results in lysosomal membrane permeabilization and 
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consequently release in the cytosol of proteases of the cathepsin family, which are 
involved in the activation of apoptotic pathways [32]. 
Additionally, cisplatin interacts with plasma membrane phospholipids, inducing 
plasmalemma destabilization and changes in fluidity, alterations in cholesterol 
metabolism and FAS receptor aggregation and stimulation, which activates the 
extrinsic pathway of apoptosis [33].  
Finally, as already mentioned above, cisplatin is able to react with different peptides 
and polypeptides, including endogenous nucleophiles containing sulphur 
functionalities, such as methionine, cysteine-rich proteins as metallothioneins and 
reduced glutathione (GSH). However this tripeptide seems to have a controversial 
role toward the cytotoxicity of cisplatin. Indeed, on the one hand GSH is involved in 
cisplatin detoxification, but on the other hand the platinum-GSH conjugate has been 
shown to interfere with transcription factors, leading to the arrest of the protein 
synthesis. Moreover the GSH depletion alters the redox state of the cells, increasing 
the levels of ROS. 
The formation of the Pt-DNA adducts may also interfere with the activity of DNA 
polymerase, preventing the DNA recognition by this enzyme. Otherwise cisplatin 
might directly bind the enzyme, causing its structural changes or loss of active sites 
[34]. 
1.5.3 Cisplatin side effects and chemoresistance 
The antitumor activity of cisplatin is associated to severe dose-limiting toxicities. 
Among these, nephrotoxicity represents one of the major side effects during 
chemotherapy. Indeed, about 20% of patients treated with high dose of cisplatin 
show serious renal injury and most of them experience kidney dysfunction shortly 
after initial administration. The pathophysiological phenomena involved in this kind 
of toxicity include induction of renal vasoconstriction, sequentially reduction in renal 
plasma flow, decrease of glomerular filtration rate and alterations of serum 
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creatinine, as well as of potassium and magnesium levels, which may lead to a 
permanent kidney dysfunction. The cisplatin-induced nephrotoxicity is mainly 
related to a high uptake of the platinum complex by the proximal tubular cells, due 
to a high renal expression of OCT2. Then, the renal injury may spread from this site 
to other tubular areas, such as collecting and distal tubules. However, this side effect 
can be largely controlled by administration of diuretics and adequate pre-hydration 
of the patients [35]. 
Also peripheral neurotoxicity is associated with cisplatin treatment. Early effects 
include tingling, numbness, or paresthesia and a reduction of distal vibratory 
sensitivity, while long term treatment may affect proprioception. The 
pathophysiology of this phenomenon is not completely elucidated, but it is known 
that the dorsal root ganglia (DRG) and peripheral neurons are the main target of the 
drug [36]. 
Another common type of cisplatin-related side effect is ototoxicity, due to injury of 
outer hair cells of the cochlea in the inner ear, causing functional deficits as hearing 
loss [37]. 
Moreover, hepatotoxicity, cardiotoxicity and disorders of the gastrointestinal tract 
(controlled by additional therapies with antiemetics) may be related to cisplatin 
treatment [38]. 
In addition to this plethora of toxicities, the clinical use of cisplatin is limited by 
induction of chemoresistance, which can be inherent, when the drug is inefficient 
from the initial treatment, or acquired, if the drug is effective at the beginning of the 
therapy but it loses activity over time. Resistance to cisplatin is considered a 
multifactorial event (Figure 1.8), which may be described as: 
1) pre-target resistance: it involves processes that precede the interaction 
between cisplatin and its target, hampering DNA binding. This kind of 
chemoresistance consists of reduced influx or increased efflux or both, 
leading to a minor cellular accumulation of cisplatin. Thus, it includes 
alterations in functionality, expression level or subcellular localization of 
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Ctr1, which play an important role in cisplatin uptake, or of copper P-type 
adenosine triphosphate transporters (ATP7A and ATP7B), which 
significantly mediate the drug extrusion. Other plasma membrane 
transporters, like multidrug resistance-associated protein 2 (MRP2) and 
phospholipid transporting ATPase 11B (ATP11B), participate to cisplatin 
efflux, hence promoting this kind of chemoresistance. Moreover, pre-target 
resistance is ascribed to increased levels of cytoplasmic scavenger containing 
thiols, like GSH and metallothioneins, which contribute to drug sequestration 
and inactivation; 
2) on-target resistance: it is directly related to cisplatin-induced molecular 
damage. The response of cancer cells to cisplatin is limited by the presence 
of an efficient DNA repair system. Thus, components of NER and MMR 
machinery are implicated in cisplatin resistance. 
3) post-target resistance: it is ascribed to defects in the cell death signaling 
pathways triggered by molecular lesions caused by cisplatin. Indeed, 
resistance is associated with p53 mutations but also with alterations in many 
other pro-apoptotic factors, as mitogen-activated protein kinase 14 
(MAPK14 or p38) and c-Jun N-terminal kinase 1 (JNK1), leading to a 
defective apoptosis. This process is also significantly affected by changes in 
the expression levels and functionality of BCL-2 family proteins and 
caspases; 
4) off-target resistance: it involves the activation of compensatory survival 
signals, but not directly triggered by cisplatin. For example, v-erb-b2 avian 
erythroblastic leukemia viral oncogene homolog 2 (ERBB2) overexpression 
seems to sustain cisplatin resistance in ovarian and breast carcinomas, 
delivering strong pro-survival signals through the v-akt murine thymoma 
viral oncogene homolog 1 (AKT1) axis, and regulating cell cycle arrest that 
is necessary for the repair of cisplatin-induce DNA damage. Moreover, Y-
phosphorylation-regulated kinase 1B (DYRK1B) has been suggested to 
 
 
  22 
 
promote resistance by favoring the expression of several antioxidants 
enzymes. Finally, various unspecific adaptive stress responses, like 
macroautophagy and HSPs activity, are also implicated in cisplatin resistance 
[39]. 
 
Figure 1.8: Molecular mechanisms of cisplatin chemoresistance. The picture is a modification 
of that reported in literature [39]. 
1.5.4 Second and third generation of platinum 
anticancer drugs 
Although cisplatin is a very effective anticancer drug, its benefits are limited by a 
panel of severe side effects and by inherent and acquired resistance. Thus, the 
research has moved toward the development of less toxic analogues without 
affecting success in cancer treatment. These efforts have led to the discovery of a 
second generation platinum complex, carboplatin, cis-diammine(1,1¢- 
cyclobutanedicarboxylato)platinum(II), which was approved by FDA in 1989. 
Compared to cisplatin, this drug contains the same carrier groups, so it forms the 
same adducts on DNA after acquation, maintaining the same efficacy. However, the 
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replacement of the chloride leaving groups with a cyclobutanedicarboxylate makes 
carboplatin about hundred times more inert to hydrolysis reactions, allowing the 
compound to have a higher life time. As a consequence, the presence of a more stable 
ligand has contributed to reduction of nephro-, neuro- and gastrointestinal tract 
toxicity. By contrast, myelosuppression (especially thrombocytopenia) and anemia 
are dose-limiting for carboplatin [28]. 
Later, oxaliplatin, cis-(1R,2R-cyclohexanediammine)oxalatoplatinum(II), a third 
generation of Pt(II) compound, has proved to be effective in treatment of intrinsic 
platinum-resistant tumor, as colorectal cancer. The different pharmacological 
activity is ascribed to the modification of the carrier groups: 1R,2R-
diaminocyclohexane (1R,2R-DACH) replaces the two monodentate ammine ligands 
of cisplatin. Moreover MMR system and HMG domain proteins recognize less 
efficiently oxaliplatin-induced DNA adducts. Oxaliplatin treatment is frequently 
associated with neutropenia, but the most common dose limiting toxicity is 
represented by a purely sensory peripheral neuropathy. This complex became the 
third platinum drug approved by FDA in 2002 [28]. 
Cisplatin, carboplatin and oxaliplatin are employed worldwide. On the contrary, the 
approval of other Pt(II)-based compounds is locally restricted: lobaplatin (1,2-
di(aminomethyl)cyclobutane)lactatoplatinum(II) approved in China, nedaplatin (cis-
diammineglycolatoplatinum(II)) in Japan, and heptaplatin cis-malonato[(4R,5R)]-
4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II) in Korea [40] (Figure 
1.9). 
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Figure 1.9: Main platinum complexes of second and third generation. 
In order to overcome cisplatin inactivation by thiol containing species, like GSH and 
metallothioneins, a new Pt(II)-based complex providing a steric bulk around the 
platinum core, known as picoplatin, was designed (Figure 1.10). Its efficacy against 
a wide range of cisplatin- and oxaliplatin-resistant tumor has been investigated, and 
it has been considered a promising drug candidate for small cell lung cancer therapy. 
However, unfortunately, it seems not to have a considerable antitumor activity. 
Clinical studies with picoplatin have shown dose-limiting side effects similar to 
those of carboplatin, including thrombocytopenia and neutropenia, but no marked 
neurotoxicity and nephrotoxicity have been observed [41]. 
 
 
Figure 1.10: Picoplatin. 
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1.5.5 Platinum(IV) prodrugs 
Nowadays, about 50% of all chemotherapy regimens, include a platinum drug. 
Despite their success in cancer treatment, Pt(II)-based compounds show two main 
limitations: a panel of severe side effects and the induction of chemoresistance. 
Moreover all platinum drugs used in clinic are intravenously administrated, via 
debilitating perfusion cycles, as their oral administration is hampered by acute 
emesis, toxicity to gastrointestinal tract and poor bioavailability. Thus, a large 
amount of Pt(II) complexes is lost before arriving at their final target, due to protein 
bindings in the bloodstream, giving rise to undesirable side reactions [42]. 
One strategy to overcome Pt(II) complexes limits is the use of Pt(IV) compounds. 
They have coordination number 6 associated to an octahedral geometry, so they are 
quite inert to substitution, and consequently amenable to oral administration, 
improving patients compliance. 
Their inertness increase their lifetime in the bloodstream and so the chances of 
reaching the tumor target intact. Indeed, Pt(IV) agents act as prodrugs, because they 
are activated by reduction in hypoxic conditions, typical of cancer 
microenvironment, by intracellular reducing agents, such as GSH, ascorbic acid, 
cytochrome c and other bioreductants. Pt(IV) complexes release, upon reduction, the 
corresponding cytotoxic square-planar Pt(II) drug and two axial ligands, which may 
be identical or different [43] (Figure 1.11). 
 
Figure 1.11: The so called “activation by reduction” of the inert octahedral Pt(IV) prodrug to 
square planar Pt(II) compound, with loss of the axial ligands X. The picture is a modification of 
that reported in literature [42]. 
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The choice of the six ligands (axial and equatorial) around the Pt(IV) core allows to 
modulate the pharmacokinetic profile of these prodrugs, which is related to two 
critical parameters: lipophilicity and the rate of reduction. The former affects the 
capacity to enter cancer cells by passive diffusion and the absorption by the gastro-
intestinal tract, whereas the latter refers to the kinetic of the reduction in biological 
conditions [44]. 
Up to now, some Pt(IV) compounds reached clinical trials. The most studied are 
tetraplatin, iproplatin and satraplatin (JM216) (Figure 1.12). 
Tetraplatin (or [PtCl4(DACH)], where DACH is 1R,2R-diminocyclohexane) and 
iproplatin (JM9 or cis,trans,cis-[PtCl2(ipa)2OH2], where ipa is isopropylamine) were 
abandoned, due to a severe neurotoxicity induced by the former and the minor 
efficacy than cisplatin exhibited by the latter [45]. 
Satraplatin (JM126 or cis,trans,cis-[Pt(c-C6H11NH2)Cl2(NH2)(OCOCH3)2]) is still 
undergoing clinical trials. It was evaluated in phase III in combination with 
prednisone for hormone refractory prostate cancer treatment. This Pt(IV) prodrug 
exhibits a milder toxicity and the advantage of its possible oral administration, 
compared to cisplatin [46]. 
 
Figure 1.12: The most studied Pt(IV) compounds. 
Moreover suitable axial ligands can be carefully selected to improve the 
pharmacological properties of the Pt(IV) complexes, as active tumor targeting 
agents. These ligands may selectively bind to receptors on the surface of cancer cells. 
However, some proteins, as essential nutrient receptors required for tumor growth, 
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are overexpressed in cancer cells, but are not specific for them, providing only a 
pseudo-active targeting. Alternatively, the targeting of other receptors, which may 
be unique to cancer cell, represents a very selective drug delivery method. 
Furthermore Pt(IV) complexes can be bound to different macromolecules, or 
nanoparticles, including micelles and liposomes, polymers, carbon nanotubes and 
other delivery systems. Such passive drug targeting formulations exploit the 
enhanced permeability and retention (EPR) effect, in order to better target tumor 
tissue. This effect is due to the rapid growth of solid tumors, which show large 
fenestrations between the endothelial cells of blood vessels and an absent or 
inefficient lymphatic drainage. The combination of these two phenomena allows the 
tumor to trap and retain circulating macromolecules [47]. 
Finally, bioactive molecules per se (enzyme inhibitors, epigenetic agents or 
complementary anticancer drugs), can be coordinated to the Pt(IV) core, resulting in 
a synergistic activity with Pt(II) drug. Thus, the resulting Pt(IV) species can act on 
multiple targets with higher potency and fewer side effects compared to single-target 
drugs, being considered multi-action agents (combo) [44]. Since different 
mechanisms of action have been pointed out in studies about pharmacological 
activity, toxicity and chemoresistance of cisplatin, this drug itself may be regarded 
as a multi-target drug. Indeed, although genomic DNA is considered as its main 
cellular target, several other interactions with cisplatin are suggested by multiple 
disciplines, as previously described. 
Moreover, Pt(IV) complexes are more or less potent oxidizing agents per se, which 
can alter the cellular redox homeostasis, increasing the ROS level and reducing the 
mitochondrial membrane potential. This creates a vicious cycle, inducing oxidative 
stress, which concurs to bringing cells to apoptosis. As previously reported, also 
cisplatin itself, albeit to a lesser extent, can generate ROS. This effect is especially 
evident for Pt(IV) compounds bearing efficient ROS-amplifying modulators. This 
may be a further advantage, since cancer cells are more sensitive to oxidative stress, 
having a higher basal level of ROS compared to their healthy counterparts [48] [49]. 
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Chapter 2 
Outline of the thesis 
Nowadays cancer remains one of the major causes of death. In the field of the 
anticancer therapy, the FDA approved Pt(II)-based drugs, cisplatin, carboplatin and 
oxaliplatin, play an important role. They are DNA-damaging chemotherapeutic 
agents used worldwide, especially in combination therapy, being administered in 
50% of chemotherapeutic regimens in the clinic. However, the antitumor activity of 
Pt(II) drugs is limited by severe systemic toxicity, induction of inherent or acquired 
chemoresistance, and poor water solubility and pharmacokinetic profile. The 
opportunity to overcome some of these limits is offered by octahedral Pt(IV)-based 
complexes. They are quite inert to substitution and reach intact cancer cells, 
minimizing the side effects and the off-target reactions typical of the more reactive 
Pt(II) counterparts. Indeed, Pt(IV) agents act as prodrugs, since they are reduced in 
the hypoxic cancer milieu to the corresponding cytotoxic Pt(II) metabolite (the so-
called activation by reduction) with the simultaneous release of two ligands from the 
axial positions. Thus, suitable axial ligands can be carefully selected to improve the 
pharmacological properties of such Pt(IV) complexes. Additionally, these ligands 
can also be bioactive molecules per se, providing a synergistic or adjuvant activity 
with that of the Pt(II) drugs, hence the resulting Pt(IV) conjugates could be 
considered dual- or multi-action agents, with a great advantage in the combinatory 
approach. 
The aim of this Ph.D. work is focused on the evaluation of the biological properties 
of several newly designed, synthetized and characterized bifunctional, or better 
multifunctional, Pt(IV) prodrug candidates. 
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In particular, the anticancer activity of such molecules has been investigated as 
reported below. 
1) Cisplatin-based Pt(IV) complexes containing the histone deacetylase inhibitor 
2-(2-propynyl)octanoate (POA): 
¨ In vitro studies of the antiproliferative activity, cellular accumulation, DNA 
platination, and epigenetic activity on human cancer cell lines with different 
sensitivity. 
¨ Evaluation of the in vivo activity of this multi-action prodrug in a model of 
solid tumor (murine Lewis lung carcinoma). 
2) Pt(IV) complexes based on the oxaliplatin-analogue cis-
dichlorido(cyclohexane-1R,2R-diamine)platinum(II) (or [PtCl2(dach)]) and 
containing POA: 
¨ Evaluation of in vitro activity (antiproliferative activity, cellular uptake and 
epigenetic properties) on human and mouse colon cancer cell lines. 
¨ The in vivo activity of this compound was investigated on a pool of 
immunocompetent BALB/c mice bearing the highly aggressive syngeneic 
CT26 mouse colon carcinoma. Particularly, this part of the work is focused 
on the study of immunogenic cell death induction. 
3) Comparisons of two series of asymmetric Pt(IV) complexes, cisplatin- or dach-
based, containing the bioactive axial MCFA ligands clofibrate (2-(p-
chlorophenoxy)-2-methyl- propionic acid, or heptanoate or octanoate: 
¨ Investigation of the in vitro biological properties of couples of complexes. In 
order to demonstrate the selectivity towards human colon cancer cell lines 
conferred by the dach carrier ligand, the antiproliferative activity, as well as 
the cellular uptake, of the two series of Pt(IV) complexes was evaluated. 
¨ Moreover, the long-term effects of the Pt(IV) treatment were studied on 3D 
multicellular tumor models, known as spheroids, which more accurately 
resemble the conditions of in vivo tumor tissue. 
 
 
  35 
 
4) Cisplatin-based Pt(IV) complexes containing Non-Steroidal Anti-inflammatory 
Drugs (NSAIDs), ketoprofen or naproxen, acting as inhibitors of both 
cyclooxygenases, COX-1 and COX-2: 
¨ Evaluation of the in vitro biological activity on a panel of human cancer cell 
lines. Particularly, antiproliferative activity, synergism between cisplatin and 
NSAIDs, cellular accumulation and modulation of the expression of NSAIDs 
target genes were studied.  
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Chapter 3 
Unsymmetric cisplatin-based Pt(IV) 
derivative containing a novel Histone 
DeACetylase inhibitor (HDACi): a very 
efficient multi-action antitumor prodrug 
candidate 
3.1 Introduction 
In order to increase antitumor efficacy of chemotherapy, usually, clinicians combine 
the FDA approved Pt(II) drugs with adjuvant agents. As previously mentioned 
(Chapter 1), the Pt(IV) derivatives are ideally suited for such a combination therapy 
since bioactive molecules can be coordinated as axial ligands in the octahedral 
assembly of the complexes, generating an ideally synergistic anticancer action when 
released along with the Pt(II) drug upon reduction [1].  
There is growing interest in the co-administration of cisplatin with Histone 
DeACetylase inhibitors (HDACi) [2] [3]. They increase the acetylation level of 
histones (especially of their lysine residues) in chromatin, thus weakening the 
histone-DNA interactions and exposing nuclear DNA to the action of DNA-
damaging chemotherapeutics as cisplatin. These features enhance tumor growth 
suppression and induce apoptosis [4] [5]. Moreover, HDACi, being epigenetic 
agents, alter in the meantime the expression of several genes, thus affecting the cell 
fate. In particular, HDACi can modulate inter alia the expression and functions of 
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DNA-repair proteins, further increasing the persistence and efficacy of the Pt-DNA 
adducts [6] [7].  
HDACi consist of two main chemical families: hydroxamic acids (e.g. 
suberoylanilide hydroxamic acid, SAHA or Vorinostat) and medium-chain fatty 
acids (MCFAs) or, more precisely (at physiological pH), their corresponding anions. 
Unfortunately, the highly effective SAHA requires heavy chemical modifications to 
coordinate the metal core [8]. On the contrary, MCFAs (e.g. 2-propylpentanoate or 
valproate, VPA, clinically employed as anticonvulsant agent, and phenylbutyrate, 
PhB, orphan drug used to treat urea cycle disorders) [9] [10], have been easily 
conjugated to the metal core via “esterification” reaction of hydroxido Pt(IV) 
synthons [11] [12]. These derivatives, based on the square-plane arrangement of 
cisplatin or oxaliplatin and containing one or two MCFA molecules linked in axial 
position, have been actively studied in the context of the antitumor dual-, or better 
multi-action, strategy [13].  
The biological properties of a new cisplatin-based Pt(IV) prodrug, containing an inert 
acetato and the bioactive 2-(2-propynyl)octanoato (POA) as axial ligands (1) are here 
reported. Indeed, it has been demonstrated that POA is more potent than VPA in 
inducing histone hyperacetylation in cerebellar granule cells, and in exhibiting 
antiproliferative and neurotrophic activity [14]. Since POA is a chiral molecule, the 
activity of the racemate (1), as well as that of the corresponding isomers (1R and 
1S), was investigated and compared to that of cisplatin and of compound 2, a 
cisplatin-based Pt(IV) complex with two VPA molecules as axial ligands (Figure 
3.1). 
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Figure 3.1: Sketch of the Pt(IV) complexes under investigation. 
3.2 Material and methods 
3.2.1 Cell culture 
Human cancer cell lines were purchased from European Collection of Cell Cultures 
(ECACC, UK) or Interlab Cell Line Collection (ICLC, Genova, Italy): ovarian 
endometrioid adenocarcinoma A2780 (ICLC HTL98008), colon carcinoma HCT 
116 (ECACC 91091005), breast ductal carcinoma MCF-7 (ECACC 86012803), 
embryonal carcinoma of the testis NTERA-2 clone D1 (also known as NT2/D1, 
ICLC HTL97025), and lung adenocarcinoma A549 (ICLC HTL03001). A2780 and 
A549 cells were grown in RPMI 1640, whereas McCoy’s 5A was used for HCT 116, 
Dulbecco’s Modified Eagle’s Medium (DMEM) for NT2/D1, and Minimum 
Essential Medium (MEM) supplemented with non-essential amino acids for MCF-
7. All media were supplemented with L-glutamine (2 mM), penicillin 100 IU mL-1, 
streptomycin (100 mg L-1) and 10% heat inactivated fetal bovine serum (FBS). 
Media and supplements were purchased by Sigma-Aldrich or Life Technologies. 
Cell culture and treatment were carried out at 37 °C in a 5% CO2 humidified 
chamber. 
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3.2.2 Compounds and drug candidates 
The Pt(IV) complexes under investigation were designed, synthetized and 
characterized in Prof. Osella’s bioinorganic laboratory (University of Piemonte 
Orientale, Dipartimento di Scienze e Innovazione Tecnologica (DiSIT), Italy). In 
particular, the starting material cisplatin was oxidized with hydrogen peroxide in 
water or acetic acid to get di- or mono-hydroxido intermediates. These synthons 
reacted with the HDACi molecules through substitution of one or both their 
carboxylic groups [15] (Scheme 1). 
 
Scheme 1: Synthetic pathway for the synthesis of compounds 1 and 2. 
In order to prepare the stock solutions of the complexes under investigation for the 
following biological tests, cisplatin (Sigma-Aldrich) was dissolved in 0.9% w/v 
NaCl aqueous solution brought to pH = 3 with HCl (final stock concentration 1 mM), 
whereas the Pt(IV) complexes were dissolved in ethanol (final stock concentration 5 
mM) and stored at -18 °C. The stock concentrations were checked by means of ICP-
OES measurements. The mother solutions were diluted in complete medium to the 
required concentration range and, where present, the total co-solvent concentration 
never exceeded 0.2% (this concentration was found to be non-toxic to the cells 
tested). A commercial racemic mixture of POA (stock concentration 4.8 M) was 
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purchased by Tokyo Chemical Industry (TCI), whereas VPA (Sigma-Aldrich) was 
freshly dissolved in 0.9% w/v NaCl aqueous solution (final stock concentration 1 
M). 
3.2.3 Antiproliferative activity 
To assess the growth inhibition of the compounds under investigation, a cell viability 
test, i.e. the resazurin reduction assay was used [16] (Scheme 2). Briefly, 2×103/well 
cells were seeded in black sterile tissue-culture treated 96-well plates. At the end of 
the treatment, viability was assayed by 100 µg mL-1 resazurin (Acros Chemicals, 
France) in fresh medium for 1 h at 37 °C, and the amount of the reduced product, 
resorufin, was measured by means of fluorescence, measured at excitation 535 nm 
and emission 595 nm with a Tecan Infinite F200Pro plate reader (Tecan Austria). In 
each experiment, the cells were challenged with the drug candidates at different 
concentrations and the final data were calculated from at least three replicates of the 
same experiment carried out in triplicate. The fluorescence intensities of 8 wells 
containing medium without cells were used as blank. Data were normalized to 100% 
cell viability for non-treated cells. Half inhibiting concentration (IC50), defined as 
the concentration of the drug reducing cell viability by 50%, was obtained from the 
dose-response sigmoid using Origin Pro (version 8, Microcal Software, Inc., 
Northampton, MA, USA). 
 
 
 
Scheme 2: Reduction of resazurin (blue, non-fluorescent) by metabolically active cells to 
resorufin (pink, fluorescent). The picture is a modification of that reported in literature [17]. 
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3.2.4 Cellular accumulation and DNA platination 
Around 80´103 A2780 cells were seeded in 10 mm Petri dishes and treated with the 
complexes under investigations (1 µM for 1 and 10 µM for cisplatin) with the 
following schedules: 4 h CT, 24 h CT, or 4 h CT followed by 20 h R (4 h CT+20 h 
R), where CT is continuous treatment and R is recovery. At the end of the exposure, 
cells were washed three times with phosphate buffered saline (PBS), detached from 
the Petri dishes using 0.05% Trypsin 1X + 2% EDTA (HyClone, Thermo Fisher) 
and harvested in fresh complete medium. An automatic cell counting device 
(Countess®, Life Technologies) was used to measure the number and the mean 
diameter from every cell count. From the same sample, about 5´106 cells were taken 
out for cellular accumulation analysis, while about 20´106 cells were taken out for 
the DNA platination analysis. Moreover, 100 µL of medium were taken out from 
each sample at time zero to check the extracellular Pt concentration. 
For the cellular Pt accumulation analysis, the cells were transferred into a borosilicate 
glass tube and centrifuged at 1100 rpm for 5 min at room temperature. The 
supernatant was carefully removed by aspiration, while about 200 µL of the 
supernatant were left in order to limit the cellular loss. Cellular pellets were stored 
at -80 °C until mineralization. 
The measurement of the Pt content was performed by ICP-MS (Thermo Optek X 
Series 2). Instrumental settings were optimized in order to yield maximum sensitivity 
for platinum. For quantitative measurements, the most abundant isotopes of platinum 
and indium (used as internal standard) were measured at m/z 195 and 115, 
respectively. Mineralization was performed by addition of 70% w/w HNO3 to each 
sample (after defrosting), followed by incubation for 1 h at 60 °C in an ultrasonic 
bath. Before the ICP-MS measurement, the HNO3 was diluted to a final 1% 
concentration. 
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The cellular Pt accumulation was referred as ng Pt per 106 cells. In order to obtain 
the Pt cellular concentration, the total cellular volume of each sample was obtained 
considering the mean cell diameter and cell number. 
For the DNA platination analysis, the cells were transferred into a plastic tube and 
centrifuged at 1100 rpm for 5 min at room temperature. The supernatant was 
carefully removed by aspiration, and the cell pellets were stored at -20 °C until the 
total genomic DNA was extracted with a commercial kit (PerfectPure Cultured 
Mammalian Cells, 5Prime- Eppendorf), following the manufacturer’s instructions. 
Briefly, during cell lysis, DNA was purified by RNAse A and proteinase K treatment, 
then extracted on silica-based centrifugation columns. After washing, DNA was 
eluted in 300 µL of elution buffer. An amount of 8 µL of sample or elution buffer 
(used as blank) were diluted in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) 
to 80 µL, corresponding to 0.5 cm path length in UV-transparent microplates half-
area wells (UV-Star®, Greiner Bio-one). Absorbance at 260 nm (A260, relative to 
nucleic acids) and 280 nm (A280, relative to proteins) were recorded from triplicate 
wells with a Tecan Infinite F200Pro plate reader (Tecan, Austria). For each well, 
A260 and A280 were corrected by subtraction of the background, then the purity of the 
samples was verified by means of the A260 to A280 ratio, which always resulted > 2. 
After the subtraction of mean A260 of blank wells, the DNA concentration was 
computed from the corrected A260 by means of a calibration curve obtained with calf 
thymus DNA. Under these conditions an absorbance of 1 unit at 260 nm corresponds 
to 100 µg of DNA per mL. The remaining amount of DNA elution buffer was 
transferred into a borosilicate glass tube and its precise volume measured by means 
of weight to compute the total amount of DNA, then stored at -20 °C until 
mineralization. Mineralization and Pt content determination were performed as 
above reported for the whole cells. 
The level of Pt found in cells after drug treatment and normalized upon the cell 
number (cellular Pt accumulation or uptake) was expressed as ng Pt per 106 cells. 
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This parameter considers only the intracellular concentration, without taking into 
account the extracellular one. !"##$#%&	()	$*)%+" = 	 -.	()101	2"##3 
Thus, a more correct way to indicate an effective accumulation is represented by the 
“accumulation ratio”, AR: this value is the ratio between the intracellular Pt 
concentration ([Pt]IC) and the extracellular one ([Pt]EC) [18]. The mean cellular 
volume, calculated from the actual mean cell diameter measured for every sample, 
was used to obtain the cellular Pt concentration. 
45 =	 [()]89[()]:9  
Regarding DNA platination, the amount of Pt bound to DNA (experimental PDNA) 
was expressed as pg of Pt per µg of DNA experimentally found [19]. 
3.2.5 HDAC assay 
A2780 cells (50×103/well) were seeded into a transparent-bottomed, black 96-wells 
TC plate the day before treatment. Complexes were given at equitoxic concentrations 
(i.e. 5 mM POA and VPA; 1 µM cisplatin, 1, 1R, 1S, and 2) at that time point for 
24 h. The total HDAC activity was measured by means of a commercial kit (HDAC 
cell-based activity assay kit, Cayman Chemical) following manufacturer’s 
instructions. Fluorescence data were recorded at excitation l = 360 nm, emission 
l = 465 nm over a 15 min period. After blank subtraction, data were normalized on 
internal controls, i.e. the sample in the presence of trichostatin A. HDAC fold activity 
was rescaled on the non-treated control. 
 
 
  44 
 
3.2.6 Chromatin staining 
2´105 A2780 cells were seeded on Nunc™ Lab-Tek™ 4-chamber slides and allowed 
to attach for 24 h. The treatment was performed with 1 µM complex 1 or cisplatin, 
or 5 mM POA. After 4 h, the medium was replaced with the staining solution, 
consisting of 5 ng mL-1 Hoechst 33342 in Earle’s Balanced Salt solution (EBSS). 
Cells were incubated in the dark for 5 minutes, washed threefold with EBSS and 
immediately observed using a standard DAPI filter set (at 350/461 nm Exc/Em) of a 
fluorescence microscope (Zeiss Axiolab), equipped with a digital camera (Nikon 
digital Sights, DS-U3). Pictures were taken at 10´ magnification. 
3.2.7 Quantitative PCR (RT-qPCR) 
A2780 cells (2×106) were seeded on T25 flasks and allowed to attach for 24 h. The 
treatment was performed in triplicate with 1 µM solutions of complex 1 or cisplatin, 
or a 5 mM solution of POA. After 24 h, RNA was extracted with a commercial kit 
(GenElute Mammalian Total RNA Miniprep Kit, Sigma-Aldrich), then it was 
quantified and checked for purity by means of absorbance at l = 260, 280, and 340 
nm in UV-Star half area UV transparent plate (Brand) with the above-mentioned 
microplate reader. For each sample, 1 µg of RNA was retrotranscribed to cDNA with 
the Revertaid cDNA First strand kit (Thermo Fisher) using random hexamer primers 
at 42 °C, following the manufacturer’s instructions. RT-qPCR was performed in 
triplicate on each sample to detect the expression levels of p53, p21, Cyclin D1, E, 
and A1, and COX-2, and the housekeeping genes RNA18S, HPRT1, GAPDH. 
Primer sequences were designed using the NCBI tool and checked for target 
specificity including splice variants. Reactions were based on the SsoFast EvaGreen 
Supermix (Bio-Rad) in the presence of 0.4 µM primer pairs except for RNA18S (0.2 
µM), according to the manufacturer’s instructions, in a reaction volume of 10 µL. In 
order to compute reaction efficiency, a standard curve was performed for each master 
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mix. RT-qPCR was performed in triplicate using and the CFX368 thermal cycler 
(Bio-Rad). The reaction conditions were 95 °C for 1 min, followed by 45 cycles at 
98 °C for 5 s and anneal-extend step for 5 s at 60 °C, with data collection. At the end 
of these cycles, a melting curve (65 °C to 95 °C, with plate read every 0.5 °C) was 
performed in order to assess the specificity of the amplification product by single 
peak melting temperature verification. Results were normalized on the reference 
genes and on the control according to the DCq and DDCq method, respectively [20]. 
All data analyses were performed with the built-in software (CFX Manager, Bio-
Rad). 
 Gene Accession n. Forward Reverse Product length (bp) 
Cyclin D1 (CCND1) NM_053056.2 TGAGGGACGCTTTGTCTGTC GCCTTTGGCCTCTCGATACA 75 
p21 (CDKN1A) NG_009364 GCGACTGTGATGCGCTAATG GAAGGTAGAGCTTGGGCAGG 141 
COX-2 M90100.1 CCCTGAGCATCTACGGTTTG CATCGCATACTCTGTTGTGTTC 107 
Cyclin A2 (CCNA2) NM_001237.4 TGGTGGTCTGTGTTCTGTGA TGCCAGTCTTACTCATAGCTGA 136 
Cyclin E (CCNE) NM_001238 GCAGGATCCAGATGAAGAAATG TAATCCGAGGCTTGCACGTT 173 
GAPDH NG_007073.2 ATCCCTGAGCTGAACGGGAA GGCAGGTTTTTCTAGACGGC 99 
HPRT1 NM_000194.2 TTGCTTTCCTTGGTCAGGCA ATCCAACACTTCGTGGGGTC 85 
TP53 NG_017013.2 GCCCCTCCTCAGCATCTTATC CTCATAGGGCACCACCACAC 99 
RNA18SN1 NR_145820.1 CGTCTGCCCTATCAACTTTCG TGCCTTCCTTGGATGTGGTAG 124 
Table 1: Analysis of relative gene expression data using RT-qPCR. The NCBI accession number is reported along with the 5’-3’ sequence of 
the forward and reverse primer and the expected product length. 
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3.2.8 Caspase 3/7 activity 
A2780 cells (2×104) were seeded in 96-well tissue culture (TC) plates in complete 
medium, the day before treatment and then challenged with Pt complexes (1 µM) 
and MCFAs (5 mM) concentrations. After 24 h cells were washed with PBS and then 
lysed with 25 µL of lysis buffer (10 mM HEPES, 2 mM EDTA, 2 mM DTT, 0.1 % 
CHAPS, pH 7.4). The caspase 3/7 inhibitor N-Acetyl-Asp-Glu-Val-Asp-CHO (Ac-
DEVD-CHO, final concentration 0.01 g L-1) (Sigma-Aldrich) was added to control 
wells. Then, 200 µL of the caspase 3/7 fluorescent substrate N-Acetyl-Asp-Glu-Val-
Asp-7-amido-4-trifluoromethylcoumarin (Ac-DEVD-AFC, 0.01 g L-1 in lysis 
buffer) (Sigma-Aldrich) was added to all the wells and mixed. A volume of 200 µL 
of each sample was transferred to a black microtiter plate and the activity was 
followed for 1 h by means of fluorescence at excitation l = 390 nm, emission 
l = 520 nm, normalized vs. the blank. Data were normalized to residual viability and 
final fold activity (with respect to control wells) was calculated as the mean of at 
least three independent replicates performed in duplicate for each condition. 
3.2.9 Experiments with animals 
All studies involving animal testing were carried out in accordance with the ethical 
guidelines for animal research adopted by the University of Padua, acknowledging 
the Italian regulation (D.L.G.S. 116/92) and European Directive 86/609/EEC as to 
the animal welfare and protection and the related codes of practice. The experimental 
protocol was approved by the Italian Health Department according to the art. 7 of 
above mentioned D.L.G.S. 116/92. The mice were purchased from Charles River 
(Italy), housed in steel cages under controlled environmental conditions (constant 
temperature, humidity, and 12 h dark/light cycle), and alimented with commercial 
standard feed and tap water ad libitum. 
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3.2.10 In vivo antitumor activity 
Lewis Lung Carcinoma (LLC) cell line was purchased from ECACC (U.K.) and 
maintained in DMEM (Euroclone) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS; Euroclone), 10 mM L-glutamine, 100 U mL−1 penicillin, and 
100 µg mL−1 streptomycin in a 5% CO2 air incubator at 37 °C. The LLC was 
implanted intramuscularly (i.m.) as a 2×106 cell inoculum into the right hind leg of 
8-week old male and female C57BL mice (24 ± 3 g body weight). After 24 h from 
tumor implantation, mice were randomly divided into five groups (8 animals per 
group, 10 controls) and treated orally with a single daily dose of Pt(IV) complexes 
(20 mg kg−1 dissolved in a vehicle solution composed of Cremophor EL 20% v/v, 
PEG400 20% v/v, and saline solution 60% v/v) or with a daily intraperitoneal (i.p.) 
dose of cisplatin (1.5 mg kg−1 in 0.9% w/v NaCl solution) from day 7 after tumor 
inoculation (visible tumor). At day 15, animals were sacrificed, the legs were 
amputated at the proximal end of the femur, and the inhibition of tumor growth was 
evaluated based on the difference in weight of the tumor-bearing leg and the healthy 
leg of the animals expressed as a percentage referred to the control animals. Body 
weight was measured every two days and was taken as a parameter for systemic 
toxicity. All the values are the means ± SD of not less than three measurements. 
For Biodistribution studies, C57BL mice were inoculated i.m. into the right flank 
with LLC cells (2×106). After 9 days from tumor implantation, 1 and 2 were 
administered orally (by gavage) at a dose of 20 mg kg-1. After 1 and 4 h, blood 
samples were collected and subsequently animals were sacrificed. Tumor, lung, 
kidney, intestine and liver were excised. Tissues were washed in ice-cold saline and 
weighed after removing excess fluid. All samples were mineralized in HNO3 and Pt 
content in each sample was measured by graphite furnace-atomic adsorption 
spectroscopy (GF-AAS). 
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3.2.11 Statistical analysis 
Data are expressed as mean ± standard deviation of at least three experiments 
performed in triplicate and compared with a one-way ANOVA-Tukey test, even 
when not expressly indicated. The statistical significance values (p) are referred to 
control values (* p<0.05; ** p<0.01; *** p<0.001). 
3.3 Results and discussion 
3.3.1 Antiproliferative activity 
The Pt(IV) compounds 1, 1R, and 1S were tested on five human cell lines with 
different chemosensitivity: cisplatin highly sensitive ovarian carcinoma A2780 and 
testicular cancer metastatic cell tumor NT2/D1, moderately sensitive colorectal 
cancer HCT 116 and lung carcinoma A549, and scarcely sensitive breast 
adenocarcinoma MCF-7. The free ligands POA and VPA, as well as cisplatin and 2, 
were tested as reference compounds. As expected, POA resulted one order of 
magnitude more active than VPA, albeit both showed only a very modest 
antiproliferative activity when employed as a single agent. Complexes 1, 1R and 1S 
exhibited IC50 values from the low micro- to the nano-molar range, thus, they are 
one-two orders of magnitude more active than cisplatin, depending on the chemo-
sensitivity of the cell line (Table 2). Surprisingly, the mono-POA derivative 1 
showed antiproliferative activities equal or even better than those found for the bis-
VPA derivative 2 for all the cancer cell lines under study, except MCF-7. Generally, 
Pt(IV) derivatives having two hydrophobic HDACi molecules, as VPA or PhB, 
resulted to be more active in vitro than their homologues containing only one HDACi 
molecule [12]. 
 Compound IC50 (µM) A2780 NT2/D1 A549 HCT 116 MCF-7 
POA 237 ± 65 94 ± 18 520 ± 288 439 ± 279  320 ± 120 
VPA 1833 ± 734 1180 ± 120 835 ± 516 1280 ± 184 4800 ± 1131 
cisplatin 0.5 ± 0.1 0.10 ± 0.04 3.6 ± 0.9 2.3 ± 0.3 3.3 ± 0.2 
1 (8 ± 1)´10-3 (4 ± 1)´10-3 (129 ± 44)´10-3 (29 ± 12)´10-3 (474 ± 56)´10-3 
1R (13 ± 4)´10-3 (5 ± 2)´10-3 (115 ± 27)´10-3 (50 ± 24)´10-3 (215 ± 119)´10-3 
1S (14 ± 5)´10-3 (4 ± 2)´10-3 (84 ± 40)´10-3 (37 ± 2)´10-3 (301 ± 68)´10-3 
2 (11.1±0.3)´10-3 (8±5)´10-3 (158 ± 35)´10-3 (77 ± 1)´10-3 (155 ± 49)´10-3 
Table 2: Antiproliferative activity (IC50) obtained after 72 h of treatment of a panel of cancer cell lines (ovarian carcinoma A2780, testicular 
cancer metastatic cell tumor NT2/D1, colorectal cancer HCT 116, lung carcinoma A549, and breast adenocarcinoma MCF-7). IC50 data are 
means ± standard deviation of at least three independent replicates. 
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This suggests the highest HDACi ability of a single molecule of POA, released by 1, 
since it is able to offer a contribution to the overall antiproliferative activity similar 
to that produced by two molecules of VPA, released by 2. Particularly, the POA 
contribution appears to be more significant for cisplatin-sensitive cancer cell lines 
(Figure 3.2). 
 
Figure 3.2: Concentration-response curve of A2780 treated for 72h with 1 (black squares and 
line), 2 (red circle and line), cisplatin (green upward triangles and line), POA (blue downward 
triangles and line). 
Remarkably, the anti-proliferative activity of racemic 1 is similar to those of the 
enantiomers 1R and 1S. Chirality is intrinsically present in the DNA structure, thus, 
cytotoxic cisplatin analogues containing chiral diamines were reported to produce 
different conformations of DNA adducts, which, in turn, affect the DNA damage and 
hence the antitumor activity. The main example is represented by oxaliplatin: the 
(1R, 2R)-enantiomer resulted to be more potent and less toxic than its (1S, 2S) 
counterpart; indeed the former enantiomer entered the clinical use [21]. In this case, 
the chirality of the ligand plays a negligible role in the cytotoxicity, which, in 
principle, is related to the amount and kind of DNA-Pt adducts formed. Actually, the 
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electrophilic metabolite produced by 1 after reduction (i.e. cisplatin) no longer 
contains the chiral POA molecule. 
Since most of the following experiments had to be carried out at shorter time 
intervals with respect to the IC50 evaluation (72 h), an optimal concentration for the 
compounds under study had to be sought. Such a concentration should maintain an 
extensive cell viability but, in the meantime, should elicit a measurable cellular 
response. The concentrations chosen were 1 µM for the all Pt complexes and 5 mM 
for the free ligands, respectively. 
3.3.2 Cellular uptake 
Literature data demonstrated that the trafficking of Pt(IV) complexes is unassisted 
by transport proteins, as Ctr1 as far as the influx is concerned. This seems to confirm 
the previous view that Pt(IV) complexes are internalized by cells (mainly, if not 
exclusively) through passive diffusion [22]. However, recent findings suggest that 
some, still unidentified) active transport mechanisms play a role for the high cellular 
uptake of selected Pt(IV) complexes having a cisplatin-like core [23]. Moreover, 
highly lipophilic derivatives containing fatty acids could be delivered to cells by 
serum albumin and/or by lipoproteins via energy-dependent endocytosis [24]. 
The cell uptake of 1 was compared with that of 2 and cisplatin by using the 
accumulation ratio, AR. The AR is the dimensionless ratio between the intra- and 
extra-cellular Pt concentrations allowing the comparison of the uptake even at 
different concentrations of drugs, as in the actual case [18]. 
The AR of 1 was measured after 4 h continuous treatment (CT) followed by 20 h 
recovery (R) in fresh, drug-free complete medium, and 24 h CT on A2780 ovarian 
cancer cells. The recovery experiment was planned to highlight any efflux process. 
The AR of 1 enormously increased from 4 h to 24 h CT and partially dropped when, 
after 4 h CT, the incubation was prolonged in drug-free medium for additional 20 h 
(4 h CT + 20 h R) (Figure 3.3 A). 
 
 
53 
 
Moreover, the AR values of 1 (21.8±0.6), 1R (22.3±1.3) and 1S (22.9±1.4), 
measured after 4 h CT on A2780, were almost identical within the experimental 
error, indicating that the two enantiomers were taken up equally by cells. 
Since the Pt(IV) derivatives are believed to enter cells by passive diffusion, 
surprisingly, the AR values of 1 and 2 are very similar (21.8 vs. 18.6) [11], pointing 
out the lack of correlation between lipophilicity, due to the presence of MCFAs 
molecules as axial ligands, and cellular accumulation. 
The DNA platination level (expressed as pg of Pt per µg of DNA, PDNA) of complex 
1 was also evaluated and compared with that of cisplatin: after a 4 h CT was similar 
to that obtained from the treatment with cisplatin at tenfold higher concentration (i.e. 
1 vs. 10 µM, respectively). Although the recovery period (20 h) caused a significant 
(p < 0.05) decrease for both complexes, the PDNA of 1 remained higher than that of 
cisplatin, and the gap hugely increased after a 24 h CT (Figure 3.3 B). So, 1 produced 
more abundant Pt-DNA adducts than a tenfold cisplatin concentration treatment. 
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Figure 3.3: (A) Accumulation ratio (AR) and (B) DNA platination PDNA (pg Pt µg-1 DNA) 
measured on A2780 cells after treatment with cisplatin (10 µM, red bars) and 1 (1 µM, yellow 
bars) for i) 4h continuous treatment (CT), ii) 4h CT followed by 20h recovery in fresh, drug-
free complete medium, and iii) 24h CT. Data are means ± standard deviations of three 
experiments in triplicate, compared with a one-way ANOVA-Tukey test (* p<0.05; ** p<0.01; 
*** p<0.001 for the comparison with the data at 4h and 24h; ° p<0.05; °° p<0.01; °°° p<0.001 
for the comparison between 1 and cisplatin). 
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3.3.3 Epigenetic activity 
Because of the well-known HDAC inhibition activity of free POA (it induces a 
strong histone H3 acetylation [14]), a HDAC activity assay on whole cells was 
performed after 24 h treatment with the drugs under investigation, in order to reveal 
the average activity of all the HDAC enzymes.  
A robust inhibition (around 40%) of HDAC activity following a 24 h treatment with 
the free MCFAs, POA and VPA (both 5 mM) was observed, whereas the Pt(IV) 
complexes 1 and 2 (both 1 µM) caused a slight decrease (around 20%). Interestingly, 
racemic POA and enantiomeric-enriched R-POA and S-POA caused identical 
HDCA inhibition (within the experimental error). The same trend was found for the 
corresponding Pt(IV) derivatives, 1, 1R and 1S (Figure 3.4). 
 
Figure 3.4: Whole cellular HDAC activity in A2780 cells after 24h of treatment with 1 µM 
cisplatin, 1, 1R, 1S, 2 and 5 mM POA, R-POA, S-POA, VPA. Data are means ± standard 
deviations of three experiments in triplicate, compared with a one-way ANOVA-Tukey test (* 
p<0.05; ** p<0.01). 
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Despite the relatively modest inhibition of the overall HDAC activity, chromatin 
decondensation and DNA relaxation were clearly observed by fluorescence 
microscopy after 4h treatment of A2780 cells with 1 and POA and staining with 
Hoechst 33342 (Figure 3.5 c and d). On the contrary, the nuclei of cells exposed to 
cisplatin resulted to be more condensed (pyknotic) (Figure 3.5 b). 
 
Figure 3.5: Representative pictures of Hoechst 33342 stained A2780 cells after a 4h treatment: 
a) control; b) cisplatin; c) 1; d) POA. 
In order to better investigate the epigenetic activity of 1, a quantitative reverse 
transcription polymerase chain reaction (RT-qPCR) analysis (a powerful method to 
quantify gene expression) was performed [25]. The experiment was focused on the 
expression level of a HDACi target genes, in particular cyclooxygenase-2 (COX-2). 
Cyclooxygenases, COX-1 and COX-2, are the key enzymes in the formation of 
biological mediators of inflammation, such as prostaglandins, prostacyclin and 
thromboxane. COX-1 is constitutively expressed in most tissue, whereas COX-2 is 
induced in response to several intracellular stimuli. Thus, this enzyme plays an 
important role in inflammation and carcinogenesis. Moreover, it has been 
demonstrated that COX-2 expression is affected by treatment with HDACi [26]. As 
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expected, a striking increase of COX-2 was observed after treatment of A2780 with 
POA (5 mM) along with a significant increase caused by treatment with complex 1 
(1 µM). Conversely, cisplatin showed a negligible effect per se. 
The expression of other genes, mostly related to cisplatin activity, such as p53, p21 
and some cyclins, previously mentioned in Chapter 1, were additionally analyzed. A 
significant gene upregulation was observed for p21 after 24 h treatment with both 
cisplatin (1 µM) and POA (5 mM), whereas a more pronounced induction was caused 
by the treatment with 1 (1 µM). This underlines the synergistic activity of 1, because 
the upregulation of endogenous inhibitors of cell cycle progression, as p21, is one of 
the well-recognized mechanisms of HDACi lethality [27]. Interestingly enough, at 
the concentration (1 µM) and in the time interval (24 h) employed, the expression of 
p53 was not significantly affected (Figure 3.6). 
 
Figure 3.6: Relative expression of target genes after a 24h treatment of A2780 cells with 1 µM 
cisplatin (red bars), or 1 (grey bars), or 5 mM POA (yellow bars). Data are means ± standard 
deviations of three experiments in triplicate, compared with a one-way ANOVA-Tukey test (* 
p<0.05; ** p<0.01; *** p<0.001 with respect to not treated cells). 
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3.3.4 Cell death 
As described above (Chapter 1), the induction of apoptosis is generally related with 
caspases activation. Thus, the measurement of their activity is a convenient way to 
investigate whether the cells are undergoing apoptosis concomitant to their growing 
arrest. Indeed, the activity of caspase 3/7 was evaluated as an apoptosis marker in 
A2780 cells treated with 1 µM complex 1, 2, cisplatin and 5 mM POA, VPA. The 
ability of activation of caspase 3/7 was in the order: POA > 1 > VPA ³ 2 ³ cisplatin 
(Figure 3.7). Hence the results showed that 1 could cause apoptosis more effectively 
than cisplatin and 2. 
 
Figure 3.7: Caspase 3/7 activity assessed on A2780 cells after a 24 h treatment with 1 µM 
cisplatin, 1, 2 and 5 mM VPA and POA. The activity was normalized on residual viability, and 
on the control. Data are means ± standard deviations of three experiments in triplicate, 
compared with a one-way ANOVA-Tukey test (* p<0.05; ** p<0.01; *** p<0.001). 
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3.3.5 In vivo tumor growth inhibition 
The in vivo antitumor activity of 1 was evaluated in a model of solid tumor, 
the highly aggressive syngeneic murine Lewis Lung Carcinoma (LLC). Tumor 
growth inhibition induced by 1 was compared with that promoted by cisplatin 
and 2. From day 7 after tumor inoculation, when tumors became visible, 
tumor-bearing mice received daily doses of 1 or 2 (both 20 mg kg-1 by oral 
gavage) or cisplatin (1.5 mg kg-1, i.p.). Cisplatin treatment schedule was 
selected according to standard protocols designed to optimize its efficacy and 
minimize the occurrence of adverse events. Tumor growth was evaluated at 
day 15. The results clearly show that complex 1 was able to induce an impressive 
reduction of the tumor mass (94%) compared to that detected in vehicle-treated 
animal group (p < 0.05), whereas chemotherapy with 2 resulted in a tumor growth 
inhibition lower (68%) than that promoted by 1. Instead cisplatin induced a tumor 
regression of 75% (Table 3). 
Compound Daily 
dose [mg 
kg-1] 
Average 
tumor weight 
[g] 
Inhibition of tumor 
growth [%] 
Control 0 0.542±0.16 0 
cisplatin 1.5 0.135±0.09 75 
1 20 0.037±0.02 94 
2 20 0.181±0.08 68 
Table 3: The in vivo antitumor activity of 1, 2 and cisplatin in LLC xenograft implanted 
intramuscularly on C57BL mice. From the day 7 to 14 the animals received daily 1 and 2 
(orally) and cisplatin (intraperitoneally). At day 15 animals were sacrificed and the inhibition 
of tumor growth was measured. The values are means ± standard deviations of not less than 
three measurements. 
In addition, for the assessment of the adverse side effects, changes in the body 
weights of tumor-bearing mice were monitored at day 1 and every two days 
from day 7. The time course of body weight changes attested that cisplatin induced 
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elevated anorexia, whereas treatment with 1 and 2 induced only a slight body weight 
loss (<10%) throughout the therapeutic experiment (Figure 3.8). 
 
Figure 3.8: Body weight changes of LLC-bearing C57BL mice treated with vehicle (black 
squares), cisplatin (red circles), 1 (blue upward triangles) and 2 (green downward triangles). 
Body weight was measured at day 1 and every two days from day 7 and was taken as a 
parameter of systemic toxicity. Data are means ± standard deviations of three experiments 
performed in triplicate. 
Moreover, blood and tissue samples were collected to estimate the biodistribution 
properties of 1 and 2 in LLC-bearing mice, after 1 and 4 h following administration 
of a single oral gavage dose, and analyzed by graphite furnace atomic absorption 
spectroscopy (GF-AAS).  
Platinum concentrations in the whole blood of 1 and 2 treated mice were very 
similar, about 0.5 µg Pt mL−1 and slightly higher in blood of mice exposed to 
a longer treatment (4 h) (Figure 3.9 A). Also the contents of platinum in tissues 
of mice treated with both 1 and 2 were similar, and the highest platinum 
concentrations were found in liver followed by tumor tissue and kidney. 
Smaller amounts of platinum were detected in intestine and lung. Noteworthy, 
the results showed that a significant higher platinum content was accumulated 
into tumor mass of 1-treated mice with respect to that measured for 2 (Figure 
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3.9 B). These data show for 1 a more favorable biodistribution profile that well 
agrees with its superior in vivo antitumor efficacy. 
 
 
Figure 3.9: Total Pt levels in blood samples (A) or in organs (B) of mice treated with 1 (red 
columns) and 2 (yellow columns) after single dose oral application. Data are means ± standard 
deviations of three experiments in triplicate, compared with a one-way ANOVA-Tukey test (* 
p<0.05; ** p<0.01; *** p<0.001). 
 
 
62 
 
3.4 Conclusions 
The biological properties of the Pt(IV) antitumor multi-action prodrug 1, 
derived from cisplatin and the potent HDACi POA, have been described. They 
have been compared to that of cisplatin and 2, a cisplatin-based Pt(IV) complex 
with two VPA, a well-known HDACi, as axial ligands. Since POA has a chiral 
center, also the isomers, 1R and 1S, of 1 were tested. Compared to 1, they showed 
almost identical in vitro activity. 
The Pt(IV) complex 1, albeit it contains only one molecule of the HDACi, POA, in 
axial position, exhibits in vitro performances similar or even better to those offered 
by the Pt(IV) compound 2, featuring two HDACi (i.e. VPA) molecules. Finally, 1 
shows also definitely better anticancer activity in vivo on LLC-bearing mice than 2 
and reference cisplatin, with a more efficient biodistribution. 
 
 
 
 
 
 
 
 
 
63 
 
References 
[1] D. Gibson. Platinum(IV) anticancer prodrugs - hypotheses and facts. Dalton 
Tran. (2016) 45, 12983-12991. 
[2] M. Bots, R. W. Johnstone. Rational combinations using HDAC inhibitors. Clin 
Cancer Res (2009) 15, 3970-3977. 
[3] J. Hrebackova, J. Hrabeta, T. Eckschlager. Valproic acid in the complex therapy 
of malignant tumors. Curr Drug Targets (2010) 11, 361-379. 
[4] JE. Bolden, MJ. Peart, RW. Johnstone. Anticancer activities of histone 
deacetylase inhibitors. Nat Revi Drug Disc (2006) 5, 769-784. 
[5] M. Buchwald, OH. Kraemer, T. Heinzel, HDACi-targets beyond chromatin. 
Cancer Lett (2009) 280, 160-167. 
[6] T. Nikolova, N. Kiweler , OH. Krämer. Interstrand Crosslink Repair as a Target 
for HDAC Inhibition. Trend Pharmacol Sci (2017) 38, 822-836. 
[7] KJ. Falkenberg, RW. Johnstone. Histone deacetylases and their inhibitors in 
cancer, neurological diseases and immune disorders. Nat Rev Drug Discov (2014) 
13, 673-691. 
[8] D. Griffith, MP. Morgan, CJ. Marmion. A novel anti-cancer bifunctional 
platinum drug candidate with dual DNA binding and histone deacetylase inhibitory 
activity. Chem Commun (2009) (44), 6735-6737. 
[9] S. Minucci, PG. Pelicci. Histone deacetylase inhibitors and the promise of 
epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 6, 38-51. 
[10] M. Manal, MJN. Chandrasekar, J. Gomathi Priya, MJ. Nanjan. Inhibitors of 
histone deacetylase as antitumor agents: A critical review. Bioorganic Chemistry, 
2016, 67, 18-42. 
[11] M. Alessio, I. Zanellato, I. Bonarrigo, E. Gabano, M. Ravera , D. Osella. 
Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural 
mesothelioma cells. J Inor Biochemi (2013) 129, 52-57. 
 
 
64 
 
[12] R. Raveendran, J. P. Braude, E. Wexselblatt, V. Novohradsky, O. Stuchlikova, 
V. Brabec, V. Gandin and D. Gibson. Pt(IV) derivatives of cisplatin and oxaliplatin 
with phenylbutyrate axial ligands are potent cytotoxic agents that act by several 
mechanisms of action. Chem Sci (2016) 7, 2381-2391. 
[13] V. Novohradsky, L. Zerzankova, J. Stepankova, O. Vrana, R. Raveendran, D. 
Gibson, J. Kasparkova, V. Brabec. New insights into the molecular and epigenetic 
effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells 
Biochemical Pharmacology (2015) 95, 133-144. 
 [14] Y. Leng, Z. Marinova, MA. Reis-Fernandes, H. Nau, DM. Chuang. Potent 
neuroprotective effects of novel structural derivates of valproic acid: potential roles 
of HDAC inhibition and HSP70 induction. Neuroscience Lett (2010) 476, 127-132. 
[15] E. Gabano, M. Ravera, I. Zanellato, S. Tinello, A. Gallina, B. Rangone, V. 
Gandin, C. Marzano, MG. Bottone, D. Osella. An unsymmetric cisplatin-based 
Pt(IV) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action 
antitumor prodrug candidate. Dalton Trans (2017) 46(41):14174-14185. 
[16] E. Magnani, E. Bettini. Resazurin detection of energy metabolism changes in 
serum-starved PC12 cells and of neuroprotective agent effect. Brain Res Protoc 
(2000) 5, 266–272. 
[17] A. Walzl, C. Unger, N. Kramer, D. Unterleuthner, M. Scherzer, M. 
Hengstschläger, D. Schwanzer-Pfeiffer, H. Dolznig. The Resazurin Reduction Assay 
Can Distinguish Cytotoxic from Cytostatic Compounds in Spheroid Screening 
Assays. J Biomol Screen (2014) 19(7), 1047-59. 
 [18] A. Ghezzi, M. Aceto, C. Cassino, E. Gabano, D. Osella. Uptake of antitumor 
platinum(II)-complexes by cancer cells, assayed by inductively coupled plasma mass 
spectrometry (ICP-MS). J Inorg Biochem (2004) 98, 73-78. 
[19] M. Ravera, E. Gabano, I. Zanellato, I. Bonarrigo, M. Alessio, F. Arnesano, A. 
Galliani, G. Natile, D. Osella. Cellular trafficking, accumulation and DNA 
platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs J Inorg 
Biochem (2015) 150, 1-8. 
 
 
65 
 
[20] KJ. Livak, TD. Schmittgen. Analysis of relative gene expression data using real-
time quantitative PCR and the 2^(-ΔΔC) method. Methods (2001) 25, 402-408. 
[21] J. Malina, C. Hofr, L. Maresca, G. Natile, V. Brabec. DNA interactions of 
antitumor cisplatin analogs containing enantiomeric amine ligands. Biophysic J 
(2000) 78, 2008-2021. 
[22] E. Ratzon, Y. Najajreh, R. Salem, H. Khamaisie, M. Ruthardt, J. Mahajna. 
Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin 
resistant cancer cell lines: an in-vitro study. BMC Cancer (2016) 16, 140-150. 
[23] S. Goschl, HP. Varbanov, S. Theiner, MA. Jakupec, M. Galanski, BK. Keppler. 
The role of the equatorial ligands for the redox behavior, mode of cellular 
accumulation and cytotoxicity of platinum(IV) prodrugs. J Inorg Biochem (2016)  
160, 264-274. 
[24] V. Novohradsky, I. Zanellato, C. Marzano, J. Pracharova, J. Kasparkova, D. 
Gibson, V. Gandin, D. Osella, V. Brabec. Epigenetic and antitumor effects of 
platinum (IV)-octanoato conjugates. Sci Rep (2017) 7, Article number 3751. 
[25] T. Nolan, RE. Hands, SA. Bustin. Quantification of mRNA using real-time RT-
PCR. Nat Protoc (2006) 1, 1559-1582. 
[26] A. Fernandez-Alvarez, C. Llorente-Izquierdo, R. Mayoral, N. Agra, L. Bosca, 
M. Casado, P. Martin-Sanz. Evaluation of epigenetic modulation of cyclooxygenase-
2 as a prognostic marker for hepatocellular carcinoma. Oncogenesis (2012) 1, e23. 
[27] P. Bose, Y. Dai, S. Grant. Histone deacetylase inhibitor (HDACI) mechanisms 
of action: emerging insights. Pharmacology & Therapeutics (2014) 143, 323-336.  
 
 
66 
 
Chapter 4 
Pt(IV) multifunctional 1R,2R-diamine-
based Pt(IV) prodrug containing the 
novel HDACi, POA: induction of 
immunogenic cell death on colon cancer 
4.1 Introduction 
As previously reported in Chapter 1, the chemistry of Pt(IV) allows to design 
multifunctional prodrugs. Nowadays, the majority of such Pt(IV) anticancer 
complexes is based on the cisplatin framework, whereas the oxaliplatin scaffold is 
less employed. Importantly, in clinic oxaliplatin (Eloxatin™) is used to treat the 
advanced colorectal cancer (the third most common tumor worldwide) [1], where 
cisplatin and carboplatin exhibit minor activity [2]. The anticancer effect of 
oxaliplatin on colon cancer cells is not simply due to the DNA-damaging activity of 
the Pt-based drug (Chapter 1), but it is also related to the reversion of the 
immunoescape (one of the hallmarks of cancer, previously reported in Chapter 1). 
The reversion of the immune evasion mechanism consists in activation of the 
immune T cells, able to recognize and kill cancer cells. Considering the ability of 
immune cells to establish a specific immunological memory, T cells activation can 
ensure a protection against the specific malignant cell transformation and invasion, 
promoting a long-lasting remission. Therefore, stimulation of the antitumor T cell 
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immunity is nowadays considered the forefront strategy for the next-generation of 
anticancer therapies [3] [4]. 
The dichlorido analogue of oxaliplatin (i.e. (SP-4-2)-dichlorido(cyclohexane-1R,2R-
diamine)platinum(II), [PtCl2(dach)] (Figure 4.1), might be a good synthon for the 
design of efficient Pt(IV) combos, specifically directed towards colon cancer. This 
Pt(II) complex was originally tested along with oxaliplatin, but it was discarded 
because of its very poor water solubility and quick hydrolysis [5]. However, 
[PtCl2(dach)] exhibited good anticancer activity when gradually released from block 
copolymer micelles or lipiodol suspensions in a phase I clinical trial to treat 
hepatocellular carcinoma [6]. Thus, its transformation in a quite inert and more water 
soluble Pt(IV) complex, could ameliorate its pharmacokinetics [7] [8].  
 
Figure 4.1: The dichlorido analogue of oxaliplatin, (SP-4-2)-dichlorido(cyclohexane-1R,2R-
diamine)platinum(II), [PtCl2(dach)]. 
Epigenetic drugs, as HDACi, are gaining increasing attention for the therapy of colon 
cancer [9]. Moreover, the cisplatin-based Pt(IV) combo, 1, bearing the strong 
HDACi, POA, as axial ligand, exibithed excellent in vitro and in vivo antitumor 
activity (Chapter 3).  
For all these reasons, the biological activity on colon cancer of a new dach-based 
Pt(IV) prodrug candidate, containing POA as axial ligand, 3, was investigated 
(Figure 4.2). As reported in Chapter 3 for complex 1, since POA is a chiral molecule, 
complex 3 containing racemic POA was tested along with its separated isomers, 3R 
(containing R-POA) and 3S (containing S-POA), and the reference compounds 
cisplatin, oxaliplatin, [PtCl2(dach)], free POA, and 1 (described in Chapter 3). 
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Figure 4.2: Sketch of the Pt(IV) complexes under investigation. 
4.2 Material and methods 
4.2.1 Cell culture 
HCT 116 were purchased from ECACC, as previously reported in Chapter 3, 
whereas the other human colon carcinoma cell lines, HT29 and SW480, are a kind 
gift of Prof. Claudia Cantoni (University of Genova, Italy). The mouse colon 
adenocarcinoma CT26 cell line is a kind gif of Prof. Enzo Terreno (University of 
Turin, Italy). RPMI 1640 medium was used for SW480 and CT26, whereas HCT 
116 and HT29 were grown in McCoy’s 5A medium. All media were supplemented, 
and cell culture and treatment were carried out, as previously described in Chapter 
3. 
4.2.2 Compounds and drug candidates 
The Pt(IV) complexes under investigation were designed, synthetized and 
characterized in Prof. Osella’s bioinorganic laboratory (University of Piemonte 
Orientale, DiSIT, Italy). In particular, complex 1 were prepared as described in 
Chapter 3, whereas the synthesis of complex 3 started with the oxidation of 
[PtCl2(dach)] with hydrogen peroxide in acetic acid to get the mono-hydroxido 
intermediate. This synthon was turned into the corresponding dicarboxylato complex 
3 
3R 
3S 
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3 by reaction with POA [10]. [PtCl2(dach)] was prepared according to published 
procedures [11] [12]. 
In order to prepare the stock solutions of the complexes under investigation for the 
following biological tests, cisplatin was dissolved in 0.9% w/v NaCl aqueous 
solution brought to pH = 3 with HCl (final stock concentration 1 mM) (Chapter 3), 
oxaliplatin (Sigma-Aldrich) was dissolved in Milli-Q water, aliquoted and stored at 
–80 °C (final stock concentration 2.5 mg mL-1, 6.3 mM), whereas [PtCl2(dach)] was 
freshly dissolved in DMSO (final stock concentration 5 mM). The Pt(IV) complexes 
were dissolved in absolute ethanol (final stock concentration 5 mM) and stored at -
18 °C. The stock concentrations were confirmed with ICP-MS measurements. The 
mother solutions were diluted in complete medium to the required concentration 
range and, where present, the total co-solvent concentration never exceeded 0.1% 
v/v (this concentration was found to be non-toxic to the cells tested as control). A 
commercial racemic mixture of POA (stock concentration 4.8 M) was purchased by 
TCI (Chapter 3). 
4.2.3 Antiproliferative activity 
The growth inhibition of the compounds under investigation was assessed by means 
of the resazurin reduction assay, as described in detail in Chapter 3. 
4.2.4 Cellular accumulation 
Around 5´106 HCT 116 cells were seeded in 25 cm2 flasks and allowed to growth 
until around 80% of confluence and then treated for 4h with the complexes under 
investigations (10 µM for cisplatin, oxaliplatin and [PtCl2(dach)], 1 µM for 1 and 3) 
in complete medium. Then, the experiment was carried out as previously described 
in detail in Chapter 3. 
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4.2.5 Chromatin staining 
2´105 HCT 116 cells were seeded on Nunc™ Lab-Tek™ 4-chamber slides and 
allowed to attach for 24 h. The following day the treatment was performed with 1 
µM complex 3 or [PtCl2(dach)], or 5 mM POA. Then, the experiment was carried 
out as described in Chapter 3. Pictures were taken at 40´ magnification. 
4.2.6 In vivo experiments 
In vivo experiments were carried out at Center of Excellence for Preclinical Imaging 
of University of Turin at the BioIndustry Park of Canavese (Colleretto Giacosa, 
Italy). A total of 18 BALB/c male mice (Envigo RMS srl, San Pietro al Natisone, 
Udine, Italy) 5 weeks old at weight of 20-25 g were fed ad libitum with standard diet 
(Special Diets Services Ltd, Witham, Essex, England). During the entire period of 
the study the animals were maintained in conditioned and at limited access 
environments (mean temperature: 22°C; lighting: controlled to give a daily 12 h 
photoperiod). All the procedures involving the animals were performed according to 
the national and international laws on experimental animal (L.D. 26/2014; Directive 
2010/63/EU) and to the approved experimental protocol procedure (Authorization 
no. 229/2016-PR). No validated non-animal alternatives are known to meet the 
objectives of the study. After a period of acclimation (5 days) tumor induction was 
performed as follows. CT26 cells were grown in RPMI 1640 medium supplemented 
with 10% fetal bovine serum, 100 IU mL-1 penicillin and 100 µg mL-1 streptomycin. 
After two washes with PBS, cells (1.5´106) were suspended in 0.2 mL of serum-free 
medium and injected subcutaneously in the right flank of each mouse. Tumors were 
let grow approximately 10 days until the tumor become visible in each animal (100-
150 mm3). Then, mice were randomly assigned to 6 experimental groups (3 animals 
per group) and the chemotherapeutic treatments were started. For each 
administration route (i.e. per os and i.v.) each group received 3, oxaliplatin, or 
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vehicle. The reference drug oxaliplatin was immediately dissolved before use in 
double distilled water and the resulting solution was protected from light, whereas 3 
was dissolved in vehicle solution (20% v/v Cremophor EL, 20% v/v PEG400 and 
60% v/v saline solution). Schedules of two parallel experiments are described in 
results and discussion. Body weight was recorded every two days during the 
observation period. Animals obviously in pain or showing signs of severe distress 
were sacrificed. Criteria for making the decision to sacrifice severely suffering 
animals, and guidance on the recognition of predictable or impending death, are the 
subject of an OECD Guidance Document. 
Tumor growth was followed by electronic caliper measurement every two days. 
Tumor volume (mm3) was calculated according to the formula (W2 ´ L)/2, where W 
and L are the maximum width and length of the tumor. Quantitative evaluation of 
body weight and tumor volume were performed. The antitumor effect was evaluated 
by comparing the tumor size among groups. Magnetic Resonance Imaging (MRI) 
acquisitions were performed at the end of observation period on one representative 
animal for each experimental group. Mice were anesthetized under 0.5-2% isoflurane 
gas anesthesia (O2 95.0%). MRI was performed on a 7 Tesla MRI scanner 
(Pharmascan MRI 7T, Bruker, Germany) using Rare sequences. The T2-weighted 
images were acquired with the optimized parameters for high-resolution images with 
a good contrast to detect the tumor mass. Organs from each animal of experimental 
groups (tumor, kidneys, spleen, liver, heart, and lungs) were collected at sacrifice 
and divided in two equal parts: one part was formalin-fixed and paraffin-embedded 
and the other one was stored at -20 °C for quantitative determination of the platinum 
content. The Pt accumulation was measured by means of ICP-MS analysis on dried 
samples of 5-20 mg of each organ in triplicate after microwave-assisted digestion 
(microwave power = 1200 W, temperature = 200 °C, digestion time = 45 min, 
Milestone Start D, Milestone Srl, Sorisole, Italy) in a mixture containing 80% v/v of 
HNO3 (70% w/w) and 20% v/v of H2O2 (30% w/w) and following dilution with 1% 
 
 
72 
 
v/v HNO3. Slices (5 µm thick) were obtained from the paraffin embedded organs by 
rotative microtome and stained by hematoxylin/eosin procedure for microanatomical 
examination to identify tissue suffering and alteration. CD8 and CD68 
immunohistochemistry was performed on spleen and tumor tissue slides of several 
experimental groups to identify cytotoxic lymphocytes (namely CD8+ T cells) and 
macrophages (namely CD68+ cells); for both rabbit polyclonal anti-mouse (Abcam: 
ab203035 and ab125212, Cambridge, UK) was used as primary antibody, revealed 
using biotinylated secondary antibody and avidin/biotinylated enzyme complex 
(Vectastain Elite kit, Vector Laboratories, Burlingame, CA, USA) together with 3,3¢-
diaminobenzidine as chromogen (DAB chromogen kit Vector Laboratories, 
Burlingame, CA, USA). 
The Oxidative Stress Detection Kit (OxyIHC, S7450; Millipore USA) was used to 
perform immunohistochemical evidences about 3-induced oxidative stress in liver, 
according with manufacturer instructions. 
4.2.7 Statistical analysis 
Statistical analysis was performed as previously described in Chapter 3. 
4.3 Results and discussion 
4.3.1 Antiproliferative activity 
The half-maximal inhibitory concentrations, IC50, were measured for the Pt(IV) 
complexes 3, 3R and 3S, along with the reference compounds cisplatin, oxaliplatin, 
[PtCl2(dach)], free POA, and the racemic cisplatin-based derivate 1. The complexes 
under investigation were tested on three human colon cancer cell lines with different 
levels of aggressiveness and tumorigenicity [13], namely HCT 116, HT29 and 
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SW480. In addition, all the compounds were assayed on CT26 mouse colon 
carcinoma cell line, in the perspective of in vivo experiments. 
The results (Table 1) showed that the activity of the isomers 3R and 3S was almost 
identical, within the experimental error, to that of 3, as already observed in Chapter 
3 for the cisplatin-based analogue 1. Moreover, the Pt(IV) complexes 3, 3R and 3S 
were one or two orders of magnitude more active than the Pt(II) reference models. 
Importantly, as previously reported in Chapter 3, the free ligand POA is almost 
inactive within the same range of concentrations (IC50 > 100 µM), also on the newly 
introduced cell lines. 
Compound 
IC50 [µM] 
HCT 116 HT-29 SW480 CT26 
POA 439±279 970±80 470±90 200±20 
Cisplatin 2.3±0.3 2.7±0.1 2.6±0.2 (4.1±0.6)×10-1 
Oxaliplatin 1.2±0.1 (9.2±0.9)×10-1 (4.7±0.2)×10-1 1.5±0.5 
[PtCl2(dach)] (2.7±0.1)×10-1 (2.4±0.2)×10-1 (1.8±0.1)×10-1 (4.6±0.3)×10-1 
3 (1.0±0.1)×10-2 (1.5±0.6)×10-2 (8.1±0.8)×10-3 (7.1±0.6)×10-3 
3R (9.1±0.6)×10-3 (1.5±0.1)×10-2 (7.4±0.6)×10-3 (8.8±0.6)×10-3 
3S (1.1±0.7)×10-2 (1.3±0.4)×10-2 (8.2±0.7)×10-3 (6.3±0.8)×10-3 
1 (2.9±0.9)×10-2 (8.0±0.8)×10-2 (3.7±0.6)×10-2 (4.4±0.3)×10-2 
 
Table 1: Antiproliferative activity (IC50) obtained after 72 h of continuous treatment of human 
colon carcinomas HCT 116, HT-29, and SW480, and mouse colon carcinoma CT26 cell lines. 
Data are means ± standard deviation of at least three independent replicates. 
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4.3.2 Cellular accumulation 
The Pt cellular uptake, expressed as accumulation ratio (AR), being the ratio between 
the intra- and extracellular Pt concentration (described in detail in Chapter 3), of all 
the Pt compounds under investigation, was assessed on HCT 116 cells. 
Figure 4.3 shows that the ARs of 3, 3R and 3S are very similar to each other (within 
the experimental error) and by far higher than those of the reference drugs, cisplatin, 
oxaliplatin and [PtCl2(dach)]; this is in agreement with what reported in Chapter 3 
for the corresponding cisplatin-like Pt(IV) prodrug 1.  
 
Figure 4.3: Accumulation ratio (AR) of 3, 1, [PtCl2(dach)], cisplatin, and oxaliplatin, measured 
on HCT 116 colon cancer cells treated for 4 h with the compounds. Data are means ± standard 
deviation of at least three independent replicates and were compared to 3 by means of a one-
way ANOVA-Tukey test (no indication = not significant; * p<0.05; **p<0.01; ***p<0.001). 
 
Based on the above reported results, the following in vitro and in vivo experiments 
were planned simply employing complex 3, since its activity was comparable to that 
of the isomers 3R and 3S. 
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4.3.3 Epigenetic activity 
Two active moieties are released by compound 3 upon intracellular reduction, which 
are [PtCl2(dach)] and the axil ligand POA. On the one hand [PtCl2(dach)] undergoes 
rapid hydrolysis in the cytosol, being able to give DNA adducts. On the other hand, 
the released POA should exert its HDACi activity, as previously observed in Chapter 
3 for the cisplatin-based derivate 1. This hypothesis was verified on HCT 116 cells 
challenged for 4h with cisplatin, 3 and free POA, by means of Hoechst 33342 
staining. Indeed, this dye binds the DNA, highlighting the regions of condensed 
DNA (heterochromatin) as brighter nuclear foci that decrease in number and size 
following chromatin relaxation. Thus, punctuated nuclear pattern is visible on 
control cells and on those exposed to cisplatin (Figure 4.4 a and b), whereas 
chromatin decondensation and DNA relaxation were clearly observed in cells treated 
with 3 and POA, underlying that the epigenetic activity of free POA is retained in 
the Pt(IV) complex 3 (Figure 4.4 c and d). 
 
Figure 4.4: HCT 116 cells treated for 4 h with a) fresh medium (control); b) [PtCl2(dach)], 1 
µM; c) 3, 1µM; d) POA, 5 mM. Pictures were taken by using a fluorescence microscope 
(standard DAPI filters, 400× magnification) on living cells immediately after Hoechst 33342 
staining. 
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4.3.4 In vivo activity 
As previously reported in Chapter 1, Pt(IV) prodrugs were designed for oral 
administration, being satraplatin the prototype tested in clinical trials. However the 
predictions of anticancer activity based on in vitro experiments, are not always in 
accordance with the results of those performed in vivo, especially for Pt(IV) 
complexes orally administered [14]. 
The simultaneous presence of [PtCl2(dach)] and POA made the Pt(IV) complex 3 
very lipophilic and this could hamper oral administration. Indeed, all successful 
oxaliplatin-based Pt(IV) prodrugs containing very lipophilic axial ligands have so 
far been administered intravenously (i.v.) or intraperitoneally (i.p.) [15] [16]. 
A pool of BALB/c mice bearing the highly aggressive syngeneic CT26 mouse colon 
carcinoma, an experimental model extensively used in literature for this kind of study 
[17], was chosen as test system. Two in vivo experiments were planned in parallel 
(Scheme 1): the former (experiment I) featuring the oral administration of 3 (gavage) 
and the latter (experiment II) characterized by the administration of 3 i.v. (tail vein). 
The comparison between the two administration routes (i.e. per os and i.v.), allows 
to verify the better administration of complex 3, in terms of efficacy/toxicity 
balancing. 
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Scheme 1: General scheme of the in vivo experiments performed on BALB/c mice bearing 
syngeneic CT26 mouse colon carcinoma treated with 3. 
 
In experiment I, three animals received only the vehicle solution (20% v/v 
Cremophor EL, 20% v/v PEG400, and 60% v/v saline solution) per os (control), 
three animals received the reference drug oxaliplatin dissolved in distilled water i.v. 
(10 mg kg-1, weekly), and three animals received compound 3 dissolved in the 
vehicle solution per os (20 mg kg-1, daily). The treatment schedule for oxaliplatin 
was selected according to standard protocols designed to optimize its efficacy and 
minimize the occurrence of side effects [18]. The schedule for 3 in experiment I was 
identical to that successfully employed for the corresponding cisplatin-based Pt(IV) 
prodrug 1 and for the bis-VPA derivative 2, which is described in detail in Chapter 
3.  
As shown in Figure 4.5, the vehicle solution administered both per os and i.v. did 
not induce body weight loss in control animals, as well as the i.v. administration of 
oxaliplatin and 3 at least up to two weeks (mean body weight of each cohort ranging 
from 99 to 110% of the initial mean weight). On the contrary, administration of 3 
per os (oral gavage, 20 mg kg-1, daily) caused within a week elevated cachexia as 
demonstrated by a body weight loss >20%. Moreover, the inspected mice showed 
clear signs of pain. Therefore, for ethical reason, experiment I was stopped after a 
week (day 17) from the beginning of treatment (day 10). Despite of these heavy side 
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effects, in experiment I the tumor growth inhibition caused by 3 was higher than that 
caused by oxaliplatin (53% vs. 25% respectively) (Figures 4.6 and 4.7). 
 
Figure 4.5: Mean body weight % ± standard deviation of BALB/c mice. Black square and line: 
control; red circle and line: oxaliplatin; upward blue triangles and line: 3 per os; downward 
green triangles and line: 3 i.v.. 
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Figure 4.6: Tumor growth inhibition of subcutaneous CT26 cell implant in BALB/c mice. Data 
are means ± standard deviation. Black squares and line: control; red circles and line: oxaliplatin 
i.v.; upward blue triangles and line: 3 per os; downward green triangles and line: 3 i.v.. 
 
In experiment II, the performance of 3 (administered i.v.) was rather promising with 
respect to reference oxaliplatin. Indeed 3 caused an inhibition of tumor growth of 
56% one week after treatment and of 38% after a further week compared to 25% and 
5% caused by oxaliplatin, respectively (Figures 4.6 and 4.7). Interestingly, the route 
of administration did not affect the activity of 3, since after 1 week (day 17) almost 
the same tumor growth inhibition was observed: 53% per os vs. 56% i.v. (Figure 
4.6). Noteworthy was the persistence of the tumor growth inhibition caused by 3, 
compared to the Pt(II) reference drug, at least during the time interval of experiment 
II. Indeed, on the contrary, oxaliplatin showed decreasing activity (Figure 4.7). 
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Figure 4.7: Images panel obtained by Magnetic Resonance Imaging (MRI) acquisition of mice 
with implanted tumor (light grey mass on the left), at the beginning of the treatments (day 10), 
at the end of experiment I (day 17) and the end of experiment II (day 24). 
4.3.5 Pt accumulation and organ histology 
Organs were collected at the end of each experiment and split into two samples to 
perform both the determination of Pt organ content and microanatomical analysis. 
Complex 3 exhibited higher cellular accumulation than that of oxaliplatin in almost 
all tissues, including the tumor mass (Figure 4.8), where the values were in line with 
those observed for the same animal model treated with similar lipophilic Pt(IV) 
derivatives [16] [19]. 
 
 
81 
 
 
Figure 4.8: Pt organ accumulation (mg Pt kg-1 of dry weight mass), a) recovered at the end of 
experiment I (yellow bars: oxaliplatin i.v.; orange bars: complex 3 per os); b) recovered at the 
end of experiment II (yellow bars: oxaliplatin i.v.; orange bars: complex 3 i.v.). Data are means 
± standard deviations of three experiments in triplicate; for each organ the data of oxaliplatin 
and 3 were compared with a one-way ANOVA-Tukey test (* p<0.05; ** p<0.01; *** p<0.001). 
 
Tissue suffering and alterations induced by the treatments with oxaliplatin and 3 
were checked at the microanatomic level, by a hematoxylin/eosin staining, in the 
tumor mass and in several organs. The effect on tumor mass caused by 3 was more 
evident than that caused by oxaliplatin and was comparable in both administration 
protocols (per os and i.v.) (Figure 4.9 a, b, c), in line with the observed tumor growth 
inhibition at day 17 (Figure 4.6). Indeed, the tumor showed a remarkably different 
pattern of distribution of heterochromatic nuclei (dark cell nuclei) in both 
experiments (I and II). Whereas heterochromatic nuclei were mainly located in the 
cortical region of the control group (Figure 4.9 a), both treatments with the Pt-based 
drugs increased them in the medullary part of tumor, more evidently in the 3-treated 
group (Figure 4.9 c) than in the oxaliplatin-treated group (Figure 4.9 b). This change 
from euchromatic (pale cell nuclei) to heterochromatic nuclei within the medullary 
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region indicates an adaptive stress response that may lead to apoptotic or necrotic 
cell death (described in Chapter 1) [20] [21]. 
 
Figure 4.9: Hematoxylin and Eosin staining of organ parenchyma from animals at the end of 
experiment II. a-c: tumor parenchyma, d-f: kidney parenchyma, g-i: liver parenchyma, a-l: 
control; b-m: oxaliplatin treated; c-n: complex 3-treated (med = medullary, ctx = cortical zone 
of the tumor). 
The kidney parenchyma after oxaliplatin administration revealed wide alteration of 
microanatomical structure, resulting in diffuse eosinophilic cells and signs of 
glomerular alteration, as glomerular tuft shrinkage and hyperchromic picture (Figure 
4.9 e), typical of a clear organ suffering status, not observable in control group 
(Figure 4.9 d). Similarly, in the liver parenchyma oxaliplatin administration caused 
several signs of cytotoxicity as eosinophilic hepatocytes and remarkable increase of 
hyperchromic nuclei occurrence (Figure 4.9 h). These findings were in accordance 
with the well-known organ toxicity of oxaliplatin, and its low systemic toxicity, 
observed in terms of body weight loss (Figure 4.5) [22]. Whereas mice treated with 
3 showed lesser signs of parenchymal alteration in the kidney with respect to 
oxaliplatin (Figure 4.9 f) in both experiments. In particular, lower parenchymal 
alterations were observed after i.v. administration (experiment II) compared to the 
oral administration (experiment I) (Figure 4.10).  
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Figure 4.10: Hematoxylin and Eosin staining of kidney parenchyma; a: complex 3-treated per 
os; b: complex 3-treated i.v.. 
Also in the liver, the i.v. protocol caused minor parenchymal alterations compared 
to oxaliplatin treatment (Figure 4.9 i) in both experiments. The hepatotoxicity of Pt-
based drugs can arise from their ability to induce ROS production, leading to an 
increase of cytokines [22]. Most of the Pt(IV) prodrugs are able to increase 
intracellular basal ROS levels. This is particularly true for the Pt(IV) prodrugs 
containing in their scaffold indole carboxylic acids in axial position [23]. Metals 
catalyse oxidation of proteins introducing carbonyl groups in several amino acid 
residues in a site-specific manner [24]. Therefore, the increase of carbonyl-modified 
proteins is considered a key biomarker in detecting the direct action of ROS. For this 
reason, the immunohistochemical detection of these modified proteins in hepatocytes 
from mice treated with 3 was performed. A wide increase of carbonyl-modified 
proteins was observed in hepatocytes from mice treated with 3 per os (Figure 4.11). 
Therefore, the observed systemic toxicity of orally administered 3 might be 
attributed to the extremely high Pt accumulation into the liver (Figure 4.8). 
On the contrary, in both experiments, heart and lung did not reveal any signs of 
suffering or alteration of the organ parenchymal structure in both control and treated 
groups (Figure 4.12). 
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Figure 4.11: Images illustrating the increase of carbonyl modified proteins (brown reaction), as 
a consequence of direct ROS action. Figures a-c: liver from per os 3-treated mice; figures d-f: 
liver from i.v. 3-treated mice. 
 
 
Figure 4.12: Hematoxylin and Eosin staining of heart and lung parenchyma; a, e: control; b, f: 
oxaliplatin treated; c, g: complex 3 treated per os; d, h: complex 3 treated i.v.. 
High Pt levels were also observed in spleen following oral administration of 3 only, 
along with volume reduction (Figures 4.8 and 4.13 a, b, c). Spleen volume decrease 
is a reversible dynamic process observed in patients undergoing platinum-based 
chemotherapy. The change in spleen volume may correlate with change in the 
number and function of immune effector cells, indicating splenic activation [25]. On 
the contrary, splenic volume increase (splenomegaly) indicates oxaliplatin-induced 
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toxicity [26]. The spleen parenchyma is normally organized in several follicular 
structures representing the masses of immune effector cells (white pulp) inside a 
reddish parenchyma (red pulp) in which ageing erythrocytes, cell debris and 
pathogens are efficiently removed from blood. In both experiments, the spleen 
revealed an increase of white pulp, more significant in 3-treated group (Figure 4.13 
d, e, f, g). In particular, a remarkable increase of the white pulp was observed in the 
experiment I (Figure 4.13 f), a hint of splenic hyperactivation. 
 
Figure 4.13: Images illustrating alterations in spleen anatomy and structure. Figures a- c: spleen 
gross anatomy; a: control, b: oxaliplatin treated, c: complex 3-treated. Figures d-g: spleen 
parenchyma; d: control; e: oxaliplatin treated; f: complex 3-treated per os; g: complex 3 treated 
i.v.. 
Immunohistochemical analysis of cytotoxic lymphocytes and macrophages, namely 
CD8+ T cells and CD68+ cells, respectively, was performed. This experiment reveals 
a remarkable increase of these cells in spleen parenchyma of per os treated mice, 
further evidencing the status of splenic hyperactivation (Figure 4.14). Thus, the toxic 
response of kidney and liver and the splenic hyperactivation of white parenchyma 
points out that the protocol of oral administration of 3 has to be considered 
unsatisfactory. 
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On the contrary, the absence of toxicity, in terms of body weight loss, observed in 
experiment II correlated with the large decrease of the Pt accumulation in liver, 
kidney, and spleen (Figure 4.8). Interestingly, the splenic accumulation of oxaliplatin 
increased with the repetition of the treatment (one week and one administration for 
experiment I; 2 weeks and 2 administrations for experiment II), whereas that of 3 
decreased, probably due to the different pharmacokinetics. In particular, the two 
different administration routes induce a different occurrence of drugs at systemic 
levels, being the per os administration mediated by intestinal passing that reduce 
and/or dilute the drug bolus. For these reasons, the i.v. administration of 3 has the 
advantage of having higher antitumor effect and lower toxicity than oxaliplatin and 
a more balanced immune response than that observed for oral administration, despite 
this way was successfully employed for other Pt(IV) derivatives, as satraplatin [27]. 
 
Figure 4.14: Images illustrating the distribution of CD8+ positive lymphocytes and CD68+ 
macrophages in spleen of several experimental groups. Figures a-d: CD8+ 
immunohistochemistry in spleen parenchyma; e-h: CD68+ immunohistochemistry in spleen 
parenchyma. 
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As previously reported in the Introduction, the immunogenic activity plays an 
important role in the anticancer propensity of oxaliplatin and its Pt(IV) derivatives. 
Administration of oxaliplatin (i.p.) inhibited tumor growth and increased 
tumor-infiltrating activated cytotoxic CD8+ T lymphocytes [28] [29]. Indeed, 
oxaliplatin-treated dying cancer cells are immunogenic as they express and secrete a 
specific combination of signals. This molecule restores the recognition of cancer 
cells by phagocytes of the immune system, essential for antigen presentation to T 
cell and their differentiation into CD8+ cells [30]. These lymphocytes specifically 
recognize and kill cancer cells, even in metastatic sites, mediating the last step of the 
so-called immunogenic cell death (ICD) [4] [31]. Thus, the presence of CD8+ cells 
within the tumor mass represents an aggression by the immune system by means of 
ICD. In order to investigate the ability of compound 3 to induce ICD, a CD8 and 
CD68 immunohistochemistry was performed on tumor tissue slides. 
Accordingly, the CD8 immunohistochemistry revealed that, in control group, CD8+ 
cells were mainly located in the tumor cortical zone (Figure 4.15 a) instead of in the 
medullary zone (Figure 4.15 d) clustered in very large follicle masses indicating the 
points of initial tumor invasion. After treatment with 3, the medullary zone was 
widely invaded by CD8+ cells (Figure 4.15 f) due to the disadvantage of the cortical 
zone (Figure 4.15 c). As expected, oxaliplatin treatment also induced the CD8+ cells 
tumor invasion, albeit less evident than that induced by 3 (Figure 4.15 b, e). Thus, 
the lipophilic 3 induced a stronger ICD than oxaliplatin itself, in line with previous 
observations. 
Similarly, immunohistochemistry analysis of CD68+ macrophages showed a large 
display of these cells along tumor parenchyma. A preferential increase in CD68+ 
cells was observed in the tumor medullary zone of 3-treated animals (Figure 4.16 g, 
h). Indeed, it has been reported in literature that some lipophilic oxaliplatin-based 
Pt(IV) prodrugs exert their antitumor activity on CT26 tumors only in immune-
competent BALB/c mice, whereas immune-deficient SCID/BALB/c mice did not 
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respond to the treatment [19]. As far as 3 generates [PtCl2(dach)] after intracellular 
reduction, the carrier ligand dach seems to play a role in the ICD [30] [31]. 
 
Figure 4.15: Microphotograph panel of immunopositive CD8+ lymphocytes invading the tumor 
mass. Tumor from animals belonging to experiment II. The dark-brown areas indicate presence 
and distribution of lymphocytes. a-c: cortical zone of the tumor, d-f: medullary zone of the 
tumor; a, d: control group, b, e: oxaliplatin treated group, c, f: compound 3-treated group. 
Figure 4.16: Images illustrating the distribution of CD68+ macrophages in tumor tissue of 
several experimental groups. Figures a-d: CD68+ immunohistochemistry in tumor parenchyma, 
cortical zone; e-h CD68+ immunohistochemistry in tumor parenchyma, medullary zone. 
Figures a, e: control; b, f: oxaliplatin treated; c, g: complex 3 treated per os; d, h: complex 3-
treated i.v.. 
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4.4 Conclusions 
The in vitro activity of the Pt(IV) complex 3, based on the [PtCl2(dach)] scaffold 
and containing the chiral POA as axial ligand, was investigated on three human and 
one mouse colon cancer cell lines, and compared to that of the isomers, 3R and 3S, 
and to references cisplatin, oxaliplatin and [PtCl2(dach)]. As expected from their 
lipophilicity, all the Pt(IV) complexes were one-two orders of magnitude more active 
than the Pt(II) compounds, due to their higher cellular uptake. Moreover, the IC50 
data, as well as the cellular accumulation results, showed that the activity of the 
enriched isomers 3R and 3S was almost identical to that of 3. Therefore, the latter 
was used for the following in vivo tests, employing a pool of BALB/c mice bearing 
CT26 colon carcinoma. Orally administered 3 inhibited the tumor growth more 
efficiently than oxaliplatin (administered i.v.). However, the presence of heavy side 
effects, attributed to an extremely high Pt accumulation into the liver, limited the 
success of such protocol. Conversely, the performance of 3 administered i.v. was 
much more promising, because the tumor growth inhibition was strong and persistent 
during the time interval of the experiment. Furthermore, i.v. administered 3 showed 
superior antitumor activity than oxaliplatin, with lower nephro- and hepatotoxicity. 
Moreover, the massive presence of the activated cytotoxic CD8+  lymphocytes in the 
medullary zone of tumor parenchyma of mice treated with prodrug 3, demonstrated 
that this Pt(IV) complex induced ICD. Both metabolites, [PtCl2(dach)] and POA, 
released after intracellular reduction, likely contribute to this process. Indeed, POA, 
a potent epigenetic agent can modulate the reversion of the immunoescape, hence 
contributing to ICD, due to a more efficient antigen presentation to immune T cells.  
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Chapter 5 
Selective activity against human colon 
cancer cell lines of cyclohexane- 1R,2R-
diamine-based Pt(IV) dicarboxylato 
anticancer prodrugs 
5.1 Introduction 
The Pt(IV) compound 3 has shown a good efficacy against colon cancer, both in 
vitro and in vivo, as described in Chapter 4. Thus, in order to discover new potential 
Pt(IV) combo prodrugs active against colon cancer, the biological properties of three 
couples of asymmetric Pt(IV) species, based on cisplatin (series 4) or oxaliplatin-
like [PtCl2(dach)] (series 5) skeleton, have been investigated (Figure 5.1). One axial 
ligand consists of a MCFA unit, linked to the Pt(IV) core as an anion, clofibrate (2-
(p-chlorophenoxy)-2-methyl- propionic acid, CA) (4a and 5a), or heptanoate (HA) 
(4b and 5b), or octanoate (OA) (4c and 5c), respectively, whereas the remaining 
axial position is taken up by a biologically inactive acetate (Figure 5.1). As far as the 
chosen axial ligands are concerned, CA acts as an agonist for peroxisome 
proliferator-activated receptors (PPARs) and promotes apoptotic cell death [1], OA 
induces DNA hypermethylation and reduces mitochondrial membrane potential [2], 
whereas HA could have epigenetic activity as the other MCFA [3]. 
In this work, cisplatin, [PtCl2(dach)] and oxaliplatin were also tested for comparison 
purposes. 
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Figure 5.1: Sketch of the two series of Pt(IV) complexes under investigation. 
5.2 Materials and methods 
5.2.1 Cell culture 
A2780 and HCT116 cell lines were purchased from ICLC or ECACC respectively, 
as described in Chapter 3. HT29 and SW480, are a kind gift of Prof. Claudia Cantoni 
(University of Genova, Italy) (Chapter 4). A2780 and SW480 were grown in RPMI 
1640, whereas McCoy’s 5A medium was used for HCT 116 and HT29. All media 
were supplemented, and cell culture and treatment were carried out, as previously 
described in Chapter 3. 
 
4a 
4c 
4b 
5a 
5c 
5b 
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5.2.2 Compounds and drug candidates 
The two series of Pt(IV) complexes under investigation were designed, synthetized 
and characterized in Prof. Osella’s bioinorganic laboratory (University of Piemonte 
Orientale, DiSIT, Italy). In particular, complexes 4a-c and 5a-c were prepared 
starting from cisplatin or [PtCl2(dach)], respectively, which was oxidized with 
hydrogen peroxide in acetic acid to get mono-hydroxido intermediates. The final step 
of the synthesis involves the substitution reaction of the axial hydroxido with CA, 
HA and OA [4]. 
In order to prepare the stock solutions of the complexes under investigation for the 
following biological tests, cisplatin was dissolved in 0.9% w/v NaCl aqueous 
solution brought to pH = 3 with HCl (final stock concentration 1 mM) (Chapter 3), 
oxaliplatin was dissolved in Milli-Q water (final stock concentration 2.5 mg mL-1, 
6.3 mM), whereas [PtCl2(dach)] was freshly dissolved in DMSO (final stock 
concentration 5 mM)  (Chapter 4). The Pt(IV) complexes 4a-4c were dissolved in 
absolute ethanol (final stock concentration 3 mM), whereas 5a-5c were dissolved in 
DMSO (final stock concentration 4 mM) and stored at -18 °C. The stock 
concentrations were confirmed with ICP-MS measurements. The mother solutions 
were diluted in complete medium to the required concentration range and, where 
present, the total co-solvent concentration never exceeded 0.1% v/v (this 
concentration was found to be non-toxic to the cells tested as control). 
5.2.3 Antiproliferative activity 
The growth inhibition of the compounds under investigation was assessed by the use 
of the resazurin reduction assay, as described in detail in Chapter 3. 
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5.2.4 Cellular uptake 
A2780 cells were seeded in T25 flasks and allowed to grow until around 80% 
confluence. Then, the treatment was performed for 4 h with the complexes under 
investigations (10 µM) in complete medium. At time zero, 100 µL of medium was 
taken out from each sample to check the extracellular Pt concentration. At the end of 
the exposure, cells were washed three times with PBS, detached from the flasks using 
0.05% Trypsin 1× with 2% EDTA (HyClone, Thermo Fisher) and harvested in fresh 
complete medium. The cell pellet was lysed in 1% w/v sodium dodecyl sulphate and 
the protein content was determined by means of the bicinchoninic acid method (BCA 
assay Kit, Pierce ThermoFisher), following manufacturer’s instructions. This assay 
is based on the reduction of Cu2+ to Cu+ in alkaline conditions. The Cu+ is then 
detected by reaction with BCA, which results in a purple product with absorbance 
near 562 nm. Since the production of  Cu+ is a function of protein content, the protein 
concentration of unknown samples was determined based on a standard curve [5]. 
The exact volume of the sample was determined by weight. The cell number was 
computed by a standard curve with known amount of the same cells. Control and 
cisplatin-treated cells showed the same values as those previously obtained with the 
method described in Chapter 3. Before the ICP-MS measurement, the HNO3 was 
diluted to final 1% concentration. The level of Pt found in cells after drug treatment 
and normalized upon the cell number (cellular Pt uptake) was expressed as ng Pt per 
106 cells. In this work, the cellular Pt uptake was used, instead of AR, because the 
cells were treated with the same concentration of all the compounds under 
investigation. 
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5.2.5 3D-spheroids model 
3D-spheroids model (which is described later) from HCT 116 cells was obtained by 
using a microplate-based protocol, similar to those previously reported [6]. 500 cells 
per well were seeded in U-shaped, 96-well polypropylene plates, put on an orbital 
mixer (Rotamax 120, Heidolph Instruments) in an incubator (37 °C, 5% CO2). After 
4 days cells gave a 300–400 µm diameter spheroid. HCT 116 cells were chosen 
among the colon cancer cell lines under study since they better grow in these 
experimental conditions. 
The spheroids (after medium removal by gentle aspiration) were challenged with 
drug-containing medium (200 µL per well) for 72 h, then drug-free medium was 
replaced twice a week until the experiment was stopped. At the same time points, 
pictures of at least three spheroids per each experiment were taken at 4× 
magnification and the dimensions of spheroids were assessed using the native Leica 
Application Suite software (version 2.0, Leica Microsystems) [7]. The spheroids 
volume was calculated from the mean diameter, and reported as fold change with 
respect to the time zero of the treatment (4th day after cell seeding). 
5.2.6 Statistical analysis 
Statistical analysis was performed as previously described in Chapter 3. 
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5.3 Results and discussion 
5.3.1 Antiproliferative activity 
The half-maximal inhibitory concentrations, IC50, were determined for the Pt(IV) 
prodrugs of series 4 and 5, along with the Pt(II) parental species as references. The 
complexes under investigation were tested on four human cancer cell lines: the 
Pt(II)-sensitive A2780 ovary adenocarcinoma cells and the cisplatin poorly sensitive 
(but oxaliplatin sensitive) HCT 116, HT29 and SW480 colon adenocarcinoma cells. 
Among the compounds tested, the 5a-5c derivatives are the most active, showing 
IC50 values in the nM range (Table 1). 
Oxaliplatin was listed in Table 1 because it is the reference metallo-drugs in clinics, 
but it was excluded from the following comparisons because of its slower activation 
with respect to all its dichlorido counterparts. 
In order to extract a quantitative trend from the bulk of the IC50 data, two comparisons 
on the dichlorido complexes have been done: 
i) The ratio R of the activity of cisplatin-based Pt(IV) (series 4) vs. cisplatin 
and of the dach-based Pt(IV) (series 5) vs. [PtCl2(dach)], against each 
cancer cell line, was calculated: R = IC50 Pt(II) / IC50 Pt(IV), as the 
antiproliferative activity is the inverse of the corresponding IC50 value 
(Table 2). 
ii) The ratio R¢ of the activity of cisplatin itself and cisplatin-based Pt(IV) 
(series 4) and the activity of [PtCl2(dach)] itself and dach-based Pt(IV) 
(series 5), against each colon cancer cell line, was calculated, i.e. R¢ = 
IC50 cisplatin-based / IC50 dach-based (Table 3). 
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Compound 
IC50 [µM] 
A2780 HCT116 HT29 SW480 
cisplatin (4.6±0.3)×10-1 2.3±0.1  2.7±0.1 2.6±0.2 
[PtCl2(dach)] (7.8±0.7)×10-2 (2.7±0.3)×10-1 (2.4±0.2)×10-1 (1.8±0.1)×10-1 
oxaliplatin (1.71±0.08)×10-1 1.16±0.09 (9.2±0.8)×10-1 (4.8±0.2)×10-1 
4a (8.1±0.3)×10-2 (3.1±0.5)×10-1 (3.7±0.8)×10-1 (3.3±0.2)×10-1 
5a (1.6±0.4)×10-3 (2.8±0.9)×10-3 (3.4±0.7)×10-3 (2.1±0.9)×10-3 
4b (1.9±0.2)×10-1 (8.7±0.9)×10-1 (4.5±0.8)×10-1 (4.1±0.9)×10-1 
5b (3.1±0.2)×10-3 (2.3±0.2)×10-3 (1.6±0.6)×10-3 (2.5±0.9)×10-3 
4c (4.2±0.4)×10-2 (5.1±0.3)×10-1 (4.4±0.9)×10-1 (4.4±0.8)×10-1 
5c (3.6±0.6)×10-3 (2.6±0.8)×10-3 (2.2±0.7)×10-3 (1.9±0.6)×10-3 
 
Table 1: Antiproliferative activity (IC50) obtained after 72 h of treatment of ovarian A2780 and 
colon HCT 116, HT29 and SW480 cancer cells lines, with series 4 and series 5 complexes 
compared to cisplatin, [PtCl2(dach)] and oxaliplatin. IC50 data are means ± standard deviation 
of at least three independent replicates. 
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Compound R A2780 R HCT 116 R HT29 R SW480 
4a 6 7 7 8 
5a 49 96 71 86 
4b 2 3 6 6 
5b 25 117 150 72 
4c 11 5 6 6 
5c 22 104 109 95 
Table 2: The ratio R of the activity of cisplatin-based Pt(IV) (series 4) vs. cisplatin and the 
activity of dach-based Pt(IV) (series 5) vs. [PtCl2(dach)] against each cancer cell. R = IC50 
Pt(II) / IC50 Pt(IV). The calculated R values were rounded to the nearest integer. 
Compounds R¢ HCT 116 R¢ HT29 R¢ SW480 
cisplatin / [PtCl2(dach)] 9 11 14 
4a / 5a 111 109 157 
4b / 5b 378 281 164 
4c / 5c 196 200 232 
Table 3: The ratio R¢ of the activity of cisplatin itself and cisplatin-based Pt(IV) (series 4) and 
the activity of [PtCl2(dach)] itself and dach-based Pt(IV) (series 5) against each colon cancer 
cell line. R′ = IC50 cisplatin-based / IC50 dach-based. The calculated R¢ values were rounded to 
the nearest integer. 
The Pt(IV) complexes, either cisplatin- or dach-based, are more active than the 
corresponding Pt(II) derivatives, about one or two orders of magnitude, respectively 
(R ranges from 2 to 11 for series 4 vs. cisplatin and from 22 to 150 for series 5 vs. 
[PtCl2(dach)]). Moreover the presence of the dach carrier ligand confers selectivity 
towards colon cancer cells with respect to the two ammine carrier ligands, being this 
selectivity markedly higher for the Pt(IV) complexes (R¢ ranges from 9 to 14) than 
for the Pt(II) derivatives (R¢ ranges from 109 to 378). 
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As a possible contribution to such selectivity, it has been reported that the final 
[PtCl2(dach)] metabolite generates Pt-DNA adducts structurally different from those 
caused by cisplatin, hence having different mechanisms for their recognition and 
processing [8]. 
Furthermore, the highly tumorigenic HCT 116 cells seemed to be more sensitive to 
the presence of the dach ligand in the Pt(IV) complexes under investigation, 
compared to HT29 and SW480 cells. 
5.3.2 Cellular uptake 
Cellular uptake was measured in A2780 and HCT 116 after 4h CT with the Pt(IV) 
compounds under investigation and their Pt(II) counterparts. All Pt(IV) complexes 
were accumulated into the cells to a much greater extent compared to their Pt(II) 
parental compounds (Figure 5.2), due to the presence of MCFA axial ligands, 
increasing their lipophilicity. Moreover, the dach-based complexes 5a, 5b and 5c 
were more internalized than the cisplatin-based ones (4a, 4b and 4c) in both cell 
lines (Figure 5.2), as the dach carrier ligand itself contributes significantly to the 
increase in lipophilicity [4]. 
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Figure 5.2: Cellular accumulation (ng Pt/ 106 cells) measured on A2780 (upper graphs) and 
HCT 116 (lower graphs) cells after 4 h treatment with 10 µM cisplatin- (yellow bars) and dach-
based (orange bars) complexes compared to their Pt(II) parent compounds. Data are means ± 
standard deviations of three experiments in triplicate, compared with a one-way ANOVA-
Tukey test (* p<0.05; ** p<0.01; *** p<0.001). 
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5.3.3 Prolonged antitumor effect using 3D spheroids 
model 
The 2D cell monolayer culture model, resulting in a well-controlled and 
homogeneous environment, facilitates manipulation and microscopic analysis, but is 
limited by cellular confluence and growth stop. Moreover, such cultures do not 
perfectly simulate the solid tumor tissue and the associated cancer cellular 
microenvironment. For these reasons, several kinds of 3D cell models have been 
proposed in the field of drug discovery and screening, since they simulate features 
similar to those of in vivo tumor tissue. Among these models, multicellular tumor 
spheroids (MCTS) are one of the most common and versatile scaffold-free methods 
for 3D cell culture. They are spherical cell aggregates, consisting of an outer ring of 
proliferating cells (simulating the in vivo situation of cancer cells adjacent to blood 
vessels), of an inner concentric layer of quiescent cells and, finally, of a 
hypoxic/necrotic core (Figure 5.3). Thus, MCST resemble large solid tumors with 
respect to their volume growth kinetics, microenvironment and morphological 
features, gradients of oxygen and nutrient distribution, cell proliferations and drugs 
access [9]. In addition, they allow the extension of viability experiments for longer 
times (approximately up to two weeks) than their 2D counterparts, hence 
distinguishing between antiproliferative activity (growth decrease or arrest for a 
relatively short period and then re-growth) and cytotoxic activity (no re-growth at 
all) [10] [11]. 
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Figure 5.3: Concentric organization of tumor cells in 3D multicellular spheroids. The picture is 
a modification of that reported in literature [9]. 
MCST obtained from HCT 116 colon cancer cells (Figure 5.4) were challenged at 
around IC50 and 10 x IC50 concentrations of all the Pt complexes under investigation 
for three days, as usually performed in 2D monolayers models, followed by 11 days 
of recovery in fresh drug-free medium [12]. 
 
Figure 5.4: Image of MCTS obtained from HCT 116 cancer cells. 
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As shown in Figure 5.5, when HCT 116 spheroids were treated with Pt(II)-based 
molecules at concentration ten times higher than the IC50 value, the spheroids lost 
their integrity, giving rise to unshaped aggregates (volume dropped to zero). 
However, spheroids treated at the IC50 value with cisplatin and [PtCl2(dach)] showed 
an initial growth arrest, followed  by a volume decrease after the 10th day (Figure 5.5 
a and b), whereas oxaliplatin caused only a negligible effect (Figure 5.5 c). 
 
Figure 5.5: Fold volume increase of HCT 116 cancer cell spheroids treated from time zero 
(corresponding to compact aggregates with 400 µm diameter) to day 3 (grey lane) with around 
IC50 concentration (red circles) or 10 x IC50 concentration (upwards green triangles), with 
respect to control (black squares). The recovery in fresh medium and the size assessment were 
performed twice a week. Treatment details: a) cisplatin at 2.5 and 10 µM, b) [PtCl2(dach)] at 
0.3 and 3 µM; c) oxaliplatin at 1 and 10 µM. 
On the contrary, the Pt(IV) complexes exerted a prolonged antiproliferative action 
(Figure 5.6 and Figure 5.7). Indeed, spheroids treated with 4b, 4c, 5b and 5c 
collapsed, both for IC50 value and for ten times higher concentration treatment 
(Figure 5.6 b, c, e, f), whereas 4a and 5a seemed to be slightly less active than the 
others (Figure 5.6 a, d). Furthermore, the dach-based Pt(IV) derivatives showed a 
higher potency compared to the corresponding cisplatin-based Pt(IV) complexes on 
HCT 116 spheroids. In this case the activity is enhanced by three orders of 
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magnitude, being in the micromolar range for series 4 and in the nanomolar range 
for series 5 complexes. 
 
Figure 5.6: Fold volume increase of HCT 116 cancer cell spheroids treated  with: a) 4a at 0.3 
and 3 µM, b) 4b at 1 and 10 µM, c) 4c at 0.3 and 3 µM, d) 5a at 0.3 and 3 nM, e) 5b at 1 and 
10 nM, f) 5c at 0.5 and 5 nM. 
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Figure 5.7: Image of MCTS obtained from HCT 116 after 72h of treatment with [PtCl2(dach)] 
at 10 x IC50 concentration (a) or IC50 concentration (b) or with 5c at 10 x IC50 concentration (c) 
or IC50 concentration (d). 
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5.4 Conclusions 
The two series of new combo Pt(IV) complexes, based on cisplatin or [PtCl2(dach)] 
skeleton, exerted a marked antiproliferative activity, both on 2D monolayer cell 
cultures and on 3D multicellular spheroids, compared to their Pt(II) counterparts. 
This increase in antiproliferative activity is certainly due to a considerable 
accumulation in cancer cells of Pt(IV) prodrugs, bearing a lipophilic MCFA axial 
ligand (i.e CA, HA, OA); while the dach carrier ligand itself significantly contributes 
to such an escalation of lipophilicity. Moreover, the dach-based series showed a 
higher selectivity towards colon cancer cells, particularly on HCT 116, and the OA 
seemed to be the most effective synergistic adjuvant for Pt drugs on the tested cell 
lines. 
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Chapter 6 
Antiproliferative Activity of Pt(IV) 
Conjugates Containing the Non-
Steroidal Anti-Inflammatory Drugs 
(NSAIDs) Ketoprofen and Naproxen 
6.1 Introduction 
As reported in Chapter 1, several agents with different cellular targets have been 
coordinated to Pt(IV) complexes in order to obtain Pt(IV) bifunctional, or better 
multifunctional, species. For example, some of them contain the inhibitors of COX 
enzymes. There are two main isoform of COX, COX-1 and COX-2, responsible for 
the formation of biological mediators of inflammation (see Chapter 3). COX-1 is 
constitutively expressed in most tissue, whereas COX-2 level is generally very low, 
unless induced in response to inflammatory and other physiological stimuli. 
Moreover, COX-2 expression is also related to pathological processes. Indeed, 
enhanced COX-2 expression is found in several tumors; thus, it seems to play a role 
in carcinogenesis [1]. For these reasons, COX inhibitors, as the large family of Non-
Steroidal Anti-inflammatory Drugs (NSAIDs), have been suggested for 
chemoprevention, especially for colon adenocarcinoma [2]. NSAIDs are a 
chemically different class of drugs, employed for the treatment of fever, pain or 
inflammation. They exert analgesic and antipyretic effects through the inhibition of 
COX activity, which catalyze the conversion of arachidonic acid into prostaglandin 
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H2, which is the precursor for the synthesis of mediators of inflammation as 
prostaglandins, prostacyclin and thromboxane A2, collectively known as eicosanoids 
[3] [4]. Unfortunately, NSAIDs exerted a modest tumor growth inhibition when 
employed as a single agent; however they showed a promising anticancer activity on 
human colon carcinoma cells, when tested as adjuvant agents [5]. Up to now, the 
mechanism of action of such anticancer adjuvant effects is not completely 
understood, but both COX-dependent and -independent pathways seem to play a key 
role [3] [4]. 
Classical NSAIDs, including aspirin, naproxen, ibuprofen, indomethacin and several 
others, inhibit both COX-1 and COX-2. Regrettably, NSAIDs seem to exert the 
anticancer adjuvant properties by inhibiting the inducible COX-2 only, whereas the 
inhibition of the constitutive COX-1 is associated to undesirable side effects, such as 
gastrointestinal toxicity [6] [7] [8]. 
The first example of a Pt(IV) complex bearing an NSAID as axial ligand, i.e 
acetylsalicylic acid (2-acetoxybenzoic acid, aspirin), is known as asplatin or platin-
A (Figure 6.1). This compound showed an antiproliferative activity comparable or 
slightly higher than that of cisplatin alone and of an equimolar mixture of cisplatin 
and aspirin [9] [10] [11]. Moreover, asplatin exhibited a better in vivo antitumor 
efficacy, with milder toxicity, compared to cisplatin [10]. 
Following this research, the study of several Pt(IV) complexes, based on cisplatin, 
oxaliplatin, or kiteplatin (an isomeric form of [PtCl2(dach)], introduced in Pt-based 
drug research many years ago [12]), and containing NSAIDs (i.e indomethacin, 
ibuprofen or wogonin) as axial ligands, has been reported in literature [13] [14] [15]. 
In this work, two new cisplatin-based Pt(IV) complexes, bearing ketoprofen 2-(3-
benzoylphenyl)propanoic acid) (6) or naproxen (2-(6-methoxynaphthalen-2-
yl)propanoic acid) (7) as axial ligand (Figure 6.1), were studied against a panel of 
human cancer cell lines. Ketoprofen and naproxen are two conventional NSAID 
propionic acid derivates, acting as inhibitors of both COX-1 and COX-2 [8] [16]. 
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Cisplatin, oxaliplatin, but also asplatin and the free axial ligands (i.e ketoprofen and 
naproxen) were also tested for comparison purposes. 
 
 
 
 
 
Figure 6.1: Sketch of the Pt(IV) complexes under investigation. 
6.2 Materials and methods 
6.2.1 Cell culture 
A2780, A549 and HCT116 cell lines were purchased from ICLC or ECACC, as 
described in Chapter 3, whereas HT29 and SW480 are a kind gift of Prof. Claudia 
Cantoni (University of Genova, Italy) (Chapter 4). Biphasic malignant pleural 
mesothelioma cell line, MSTO-211H was purchased from ICLC (ICLC HL01018). 
RPMI 1640 medium was used for A2780, A549, SW480 and MSTO-211H cell lines, 
whereas HCT 116 and HT29 cells were grown in McCoy’s 5A medium. All media 
were supplemented, and cell culture and treatment were carried out, as previously 
described in Chapter 3. 
 
Asplatin or platin-A 6 7 
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6.2.2 Compounds and drug candidates 
The Pt(IV) complexes under investigation were designed, synthetized and 
characterized in Prof. Osella’s bioinorganic laboratory (University of Piemonte 
Orientale, DiSIT, Italy). In particular, complexes 6 and 7 were prepared starting from 
cisplatin, which was oxidized with hydrogen peroxide in acetic acid to get the 
corresponding mono-hydroxido intermediate. The presence of a carboxylic 
functionality in the structure of ketoprofen and naproxen allows an easy coordination 
to the Pt(IV) core through an “esterification” reaction of the hydroxido synthon with 
the acyl chloride of the NSAIDs [17]. Whereas the reference compound asplatin has 
been prepared according to the procedure reported by Dhar et al., by reacting (OC-
6-44)-diamminedichloridodihydroxidoplatinum(IV) with the anhydride of 
acetylsalicylic acid [18]. 
In order to prepare the stock solutions of the complexes under investigation for the 
following biological tests, cisplatin was dissolved was dissolved in 0.9% w/v NaCl 
aqueous solution brought to pH = 3 with HCl (final stock concentration 1 mM) 
(Chapter 3), whereas oxaliplatin was dissolved in Milli-Q water (Chapter 4). All 
Pt(IV) complexes were dissolved in absolute ethanol (final stock concentration 5 
mM for asplatin and 6, and 1 mM for 7) and stored at -18 °C. The mother solutions 
were diluted in complete medium to the required concentration range and, where 
present, the total co-solvent concentration never exceeded 0.2% (this concentration 
was found to be non-toxic to the cells tested as control). The stock concentrations 
were confirmed with ICP-MS measurements. Aspirin (Sigma-Aldrich), ketoprofen 
and naproxen (Alfa Aesar-Thermo Fisher Scientific) were freshly dissolved in 0.1 M 
NaHCO3 (final stock concentration 5 mM for aspirin and ketoprofen and 2.5 mM for 
naproxen). 
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6.2.3 Antiproliferative activity and combination index 
The growth inhibition of the compounds under investigation was assessed by the use 
of the resazurin reduction assay, as described in detail in Chapter 3. 
In order to verify the synergy between NSAIDs and cisplatin, HCT 116 and HT-29 
cells were treated with increasing concentrations of cisplatin, ketoprofen or 
naproxen, and a mixture cisplatin:NSAIDs in a fixed 1:500 molar ratio, according to 
their respective IC50 values. The experiment was repeated three times. According to 
the method of Chou and Talalay [19] [20] [21], the interaction between cisplatin and 
NSAIDs was computed in terms of combination index (CI) for mutually non-
exclusive drugs by using the following equation: 
!" = !1%!1& + !2%!2& + !1%!2%!1&!2&  
where C1 and C2 are the concentrations of drugs 1 and 2 used in the mix (C1m and 
C2m) or alone (C1a and C2a) to obtain the same fraction affected (fa,), i.e. the fraction 
of cells affected by such a treatment. Based on the actual experimental data, the CI 
values were calculated by solving the equation over an entire range of fa (from 0.1 to 
0.9, obtained from 90 to 10% level of residual viability, upon sigmoidal regression). 
These data were then used to generate CI vs. fa, plots, which is an effect-oriented 
means of presenting synergism or antagonism. CI is defined in such a way that CI = 1 
indicates simple additive effect, and CI < 1 and a CI > 1 indicate synergism and 
antagonism, respectively. 
6.2.4 Cellular uptake 
Around 5x106 A2780 cells were seeded in 25 cm2 flasks and allowed to growth until 
around 80% of confluence and then treated for 4h with the complexes under 
investigations (10 µM) in complete medium. Then, the experiment was carried out 
as previously described in detail in Chapter 3. 
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6.2.5 Quantitative PCR (RT-qPCR) 
HCT 116 and A549 cells (2×106) were seeded on 25 cm2 flasks and allowed to attach 
for 24 h. The treatment was performed with equitoxic concentrations (i.e., HCT 116: 
3 µM for both complexes 6 and 7, 1 mM for both ketoprofen and naproxen, and 30 
µM for cisplatin; A549: 5 µM for both complexes 6 and 7, 1 mM for both ketoprofen 
and naproxen, and 50 µM for cisplatin). After 24 h, RNA was extracted and purified 
by DNAse treatment with a commercial kit (RNASPIN MINI, GE Healthcare); then 
it was quantified, checked for purity and retrotranscribed (RT) to cDNA as 
previously described in Chapter 3. RT-qPCR was performed in triplicate on each 
sample (10 ng) to detect the expression levels of BAD, BAX, COX-2, NAG-1, and 
the reference genes RNA18S, HPRT1, GAPDH. Primer sequences were designed 
using the NCBI tool and checked for target specificity including splice variants 
(Table 1). Reactions and all data analyses were performed as previously described in 
Chapter 3. 
 
 
 
 Gene Accession n. Forward Reverse Product length (bp) 
COX-2 M90100.1 CCCTGAGCATCTACGGTTTG CATCGCATACTCTGTTGTGTTC 107 
GAPDH NG_007073.2 ATCCCTGAGCTGAACGGGAA GGCAGGTTTTTCTAGACGGC 99 
HPRT1 NM_000194.2 TTGCTTTCCTTGGTCAGGCA ATCCAACACTTCGTGGGGTC 85 
RNA18SN1 NR_145820.1 CGTCTGCCCTATCAACTTTCG TGCCTTCCTTGGATGTGGTAG 124 
BAX NM_001291428.1 GACCATCTTTGTGGCGGGAG GAGGAAAAACACAGTCCAAGGC 94 
BAD NM_004322.3 GAGACCTGTGCGCCGTCA  AGGACCTCAGTCTCCCCTCAG 74 
Bcl2a NM_000633.2 CTTTGAGTTCGGTGGGGTCA GGGCCGTACAGTTCCACAAA 162 
NAG-1/GDF15 NM_004864.3 TTGCGGAAACGCTACGAGG GCACTTCTGGCGTGAGTATCC 115 
 
Table 1: Analysis of relative gene expression data using RT-qPCR. The NCBI accession number is reported along with the 5’-3’ sequence of 
the forward and reverse primer and the expected product length.
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6.2.6 Statistical analysis 
Statistical analysis was performed as previously described in Chapter 3. 
6.3 Results and discussion 
6.3.1 Antiproliferative activity and combination index 
The half-maximal inhibitory concentrations, IC50, were determined for 6 and 7, along 
with the clinically-employed reference complexes cisplatin and oxaliplatin. Also 
asplatin, and free ketoprofen, and naproxen were tested for comparison purposes. Six 
human cancer cell lines were challenged with the compounds under investigation: 
lung carcinoma A549, colon adenocarcinoma HT29, HCT 116 and SW480, ovarian 
endometrial adenocarcinoma A2780, and malignant pleural mesothelioma (MPM) 
with mixed or biphasic phenotype, consisting of both epithelioid and sarcomatoid 
components, MSTO-211H. The last cell line was added to the panel since promising 
preclinical results have been reported on the activity of celecoxib on MPM, albeit 
apparently independent of COX-2 protein level [22]. 
Before the viability tests the level of COX-2 expression was evaluated in these cell 
lines by quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
[23] [24], resulting observably high in A549 and HT29, medium in HCT 116, low in 
MSTO-211H, and very low in A2780 and SW480 (Figure 6.2). 
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Figure 6.2: COX-2 relative expression in A549, HT29, HCT 116, MSTO-211H, A2780, and 
SW480 cells. Data are means ± standard deviation of at least three independent replicates and 
were compared by means of a one-way ANOVA analysis of variance-Tukey test (*p < 0.05; 
**p < 0.01; ***p < 0.001 vs. SW480). 
As shown in Table 2, at the first glance, the Pt(IV) complexes 6 and 7 appear to be 
more active than cisplatin, oxaliplatin, and also asplatin on all cell lines tested 
ranging from 2 to 24 times. Moreover, the Pt(IV) compound naproxen-bearing 7, is 
(almost always) slightly more active than the ketoprofen-bearing one 6. 
 
 
 
Compound IC50 (µM) 
 
A549 HT29 HCT 116 MSTO-211H SW480 A2780 
cisplatin 3.60±0.90 2.72±0.39 2.30±0.30 1.33±0.35 2.27±0.12 0.460±0.110 
oxaliplatin 0.74±0.25 0.92±0.08 1.16±0.09 1.01±0.55 0.48±0.02 0.171±0.008 
aspirin 1672±152 2835±885 2578±772 639±374 1607±386 1597±455 
ketoprofen 725±69 828±229 914±185 518±296 830±173 676±36 
naproxen 701±28 764±158 640±91 427±159 927±257 353±64 
asplatin 6.4±2.7 
 
4.42±0.21 
 
1.50±0.083 
 
1.74±0.21 
 
0.217±0.07 
 
0.552±0.123 
 
6 0.825±0.388  
0.486±0.235 
 
0.184±0.088 
 
0.198±0.035 
 
0.0948±0.023 
 
0.063±0.033 
 
7 0.486±0.075  
0.313±0.186 
 
0.149±0.076 
 
0.161±0.040 
 
0.0844±0.0287 
 
0.045±0.016 
 
 
Table 2: Antiproliferative activity (IC50) obtained after 72 h of treatment of a panel of cancer cell lines (lung A549, colon HT29, HCT 116 and 
SW480, ovarian A2780 and MPM MSTO-211H cancer cell lines). IC50 data are means ± standard deviation of at least three independent 
replicates. 
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In order to extract quantitative trends from the bulk of the IC50 data, the ratio R of 
the activity of cisplatin-based Pt(IV) derivatives (i.e asplatin, 6, and 7) vs. the activity 
of parent cisplatin against each cancer cell has been calculated (Table 3). As 
previously reported in Chapter 5, since the antiproliferative activity is the inverse of 
the corresponding IC50 value, it follows that: R = IC50 (cisplatin) / IC50 (Pt(IV) 
conjugates. Interestingly, the trend of the R values does not follow the level of COX-
2 expression. In particular, among the colon cancer cell lines, HCT 116 and SW480 
cells, which have lower level of COX-2 with respect to HT29, resulted to be more 
sensitive to treatments with 6 and 7. From this reason, the antiproliferative activity 
seems to be more related to the lipophilicity of the complexes [17] than to the COX-
2 expression in these tumor cell lines. Also the antiproliferative activity of the free 
NSAIDs tested seems to be unrelated to the COX-2 expression, as the IC50 values of 
ketoprofen and naproxen resulted quite similar (in the low mM range) in these cancer 
cell lines. 
Compound A549 HT29 HCT 116 MSTO-211H SW480 A2780 
asplatin 0.56 0.62 2.0 0.75 1.1 0.83 
6 4.4 5.6 17 6.7 24 7.3 
7 7.4 8.7 20 8.3 27 10 
 
Table 3: The ratio R of the activity of  Pt(IV) conjugates vs. cisplatin against each cancer cell 
line. R = IC50 cisplatin / IC50 Pt(IV) complexes. 
Moreover, the combination index (CI) values between free cisplatin and the two 
NSAIDs (i.e ketoprofen and naproxen) were calculated for HT29 and HCT 116 , two 
colon cancer cell lines showing high and medium COX-2 expression, respectively. 
In all cases, CIs resulted almost additive (around 1) for both  cell lines, once again 
independently from COX-2 expression (Figures 6.3 and 6.4). 
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Figure 6.3: a) Residual HCT 116 viability data and concentration response curves 
(four parameters logistic function) after 72 h of treatment with cisplatin (red circles), 
ketoprofen (black squares) and a mixture of cisplatin + ketoprofen (final 
cisplatin:ketoprofen ratio = 1:500, green upward triangles). Data are means ± 
standard deviation of at least three replicates. b) Fraction affected (fa) data for the 
1:500 cisplatin:ketoprofen mix were used to obtain the Combination Index (CI) value 
by using the equation of Chou and Talalay for mutually non-exclusive drugs. c) 
Residual HCT 116 viability data and concentration response curves after 72 h of 
treatment with cisplatin (red circles), naproxen (black squares) and a mixture of 
cisplatin + naproxen (final cisplatin:naproxen ratio = 1:500, green upward triangles). 
d) Fraction affected (fa) data for the 1:500 cisplatin:naproxen mix were used to obtain 
the CI value. 
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Figure 6.4: e) Residual HT29 viability data and concentration response curves after 
72 h of treatment with cisplatin (red circles), ketoprofen (black squares) and a 
mixture of cisplatin + ketoprofen (final cisplatin:ketoprofen ratio = 1:500, green 
upward triangles). Data are means ± standard deviation of at least three replicates. f) 
Fraction affected (fa) data for the 1:500 cisplatin:ketoprofen mix were used to obtain 
the CI value. g) Residual HT29 viability data and concentration response curves after 
72 h of treatment with cisplatin (red circles), naproxen (black squares) and a mixture 
of cisplatin + naproxen (final cisplatin:naproxen ratio = 1:500, green upward 
triangles). h) Fraction affected (fa) data for the 1:500 cisplatin:naproxen mix were 
used to obtain the CI value. 
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6.3.2 Cellular uptake 
The intracellular Pt accumulation of the Pt(IV) compounds 6 and 7, was assessed 
on A2780 cells and compared to that of asplatin and cisplatin. This parameter is 
here expressed as accumulation ratio (AR), i.e. the ratio between the intracellular 
Pt concentration and the extracellular one, as reported in detail in Chapter 3. The 
AR trend exhibits the differences showed in antiproliferative activity, as the 
Pt(IV)-NSAID complexes 6 and 7 were more internalized than the others two 
reference compounds (Figure 6.5). These data confirm that the trend of activity 
can be explained in terms of lipophilicity of the compounds, which affects their 
cellular uptake. Thus, these combo Pt(IV) prodrugs enter cells via passive 
diffusion (one of the main mechanism of cellular uptake of Pt(IV) complexes, 
as previously mentioned in Chapter 3) more efficiently than their Pt(II) 
counterparts. Hence this can be defined as synergistic cellular accumulation 
[25]. 
 
Figure 6.5: Accumulation ratio (AR) of cisplatin, asplatin, 6, and 7, measured on A2780 
ovarian cancer cells treated for 4 h with 10 µM concentrations of the Pt complexes. Data are 
means ± standard deviation of at least three independent replicates and were compared by 
means of a one-way ANOVA analysis of variance-Tukey test (*p < 0.05; **p < 0.01; ***p < 
0.001 vs. cisplatin). 
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6.3.3 Modulation of gene expression 
The apparent absence of relationship between COX-2 expression and sensitivity of 
different cell lines towards the Pt(IV) compounds 6 and 7 or free ketoprofen and 
naproxen suggests that these drugs might exert their antiproliferative activity through 
a COX-independent mechanism. Thus, to better understand the biological properties 
of these drugs a RT-qPCR analysis was performed on two cell lines, A549 and HCT 
116, characterized by high and low COX-2 expression, respectively. In this 
experiment the variation of the expression of five genes (i.e., BAD, BAX, BCL-2, 
COX-2 and NAG-1) was analyzed. 
Since RT-qPCR experiment had to be carried out at shorter time at shorter time 
intervals (24h) compared to the IC50 evaluation (72 h), preliminarily, to perform 
equitoxic treatments with the Pt(IV) compounds 6, 7, or the corresponding free 
NSAIDs, the IC50 values after 24 h of continuous treatment were obtained. 
As described in detail in Chapter 1, the main goal of anticancer agents is to increase 
the levels of pro-apoptotic proteins, as BAX and BAD, or decrease that of anti-
apoptotic ones, as BCL-2. Moreover, as previously mentioned, both COX-dependent 
and -independent pathways seem to play a role in the antitumorigenic mechanism of 
NSAIDs. Indeed, recent studies have reported the existence of the NSAID activated 
gene (NAG-1), which is involved in cancer development and progression [26]. It has 
been demonstrated that the induction of NAG-1 expression by NSAIDs is involved 
in pro-apoptotic and anticancer activity, both in vitro and in vivo [27]. Importantly, 
it is not influenced by COX expression [28], thus, the induced expression of NAG-1 
can be related with the antitumorigenic action of NSAIDs, as a COX-independent 
mechanism [29]. 
As shown in Figure 6.6, cisplatin, 6 and 7, had a similar effect on the expression of 
pro- and anti-apoptotic genes in both cell lines, indicating that cisplatin released by 
the activation by reduction of the Pt(IV) complexes (described in Chapter 1), plays 
the major role. Particularly, their main effects was the downregulation of anti-
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apoptotic BCL-2, more marked in A549 than in HCT 116 cells, and the upregulation 
of pro-apoptotic BAX and BAD. On the contrary, contrasting but negligible effects 
(i.e. no changes compared to the regulation threshold) were caused by free 
ketoprofen and naproxen. In addition, Pt(IV) conjugates and free NSAIDs did not 
significantly change the COX-2 expression in A549 cells, whereas it slightly 
increased in HCT 116 cells after treatment with these compounds. This effect may 
be due to a substantial contribution of cisplatin, as the Pt(II) drug itself increased the 
expression of COX-2 in HCT 116 cells. 
Interestingly, 6 and 7, and to a lesser extent, free ketoprofen and naproxen, increased 
the expression of NAG-1 in both cell lines. Also cisplatin caused the upregulation of 
this gene, thus contributing to the overall stimulation of NAG-1 expression. 
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Figure 6.6: Relative gene expression of BAD, BAX , BCL-2, COX-2 and NAG-1 in (a) HCT 
116 and (b) A-549 cells following equitoxic 24 h treatments with cisplatin, 6, 7, ketoprofen, 
and naproxen. From left to right of each sequence: control, 6 (light yellow), 7 (light green), 
ketoprofen (dark yellow), naproxen (dark green), and cisplatin (light blue). The RT-qPCR 
experiment was performed in triplicate, and results were normalized to references genes in 
untreated control. The arrows indicate the upregulated (arrow up) or downregulated (arrow 
down) gene expression with respect to internal threshold value as determined by the CFX 
Manager software. 
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6.4 Conclusions 
The Pt(IV)-NSAID complexes 6 and 7 showed higher antiproliferative activity on 
the cancer cell lines under investigation when compared to cisplatin, oxaliplatin, 
asplatin and the corresponding free NSAIDs, ketoprofen and naproxen. The trend of 
activity can be explained in terms of lipophilicity of the compounds, that affects their 
cellular accumulation, hence defined as synergistic cellular accumulation. On the 
contrary, the trend of activity seems to be scarcely dependent on COX-2 gene 
expression, suggesting that a COX-2-independent mechanism may play a role. This 
mechanism has been tentatively identified in the activation of the gene NAG-1, 
having antitumorigenic and pro-apoptotic activity, that may be linked, at least in part, 
to the chemopreventive activity of NSAIDs. However, analyzing the variation of 
pro-apoptotic BAD and BAX and anti-apoptotic BCL-2 genes, it appears clearly that 
cisplatin, released after Pt(IV) ® Pt(II) reduction, is the component of the combos 
mainly responsible for the overall antiproliferative activity, also because of its own 
NAG-1 activation. Thus, most of the biological effects of the Pt(IV) complexes 6 
and 7 are related to the releasing of cisplatin. The NSAID axial ligands only increase 
the overall lipophilicity and hence the cellular accumulation of these combos, 
offering a minor (additive) contribution in terms of NAG-1 activation. 
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Chapter 7 
Concluding Remarks and Perspectives 
Despite the progress made by the research, cancer remains one of the major causes 
of death worldwide. Nowadays, immunostimulating- and targeted-therapies are 
considered among the most promising antitumor strategies to get high therapeutic 
antitumor effects with mild systemic toxicity. However, traditional cytotoxic (DNA-
damaging) chemotherapy is still one of the treatments of choice for several highly 
aggressive cancers. Most of such chemotherapeutic schedules consist of the so-called 
combination therapy (i.e. the administration of two or more additive, or better 
synergistic, drugs together). Within this context, the three FDA-approved Pt(II) 
drugs, cisplatin, carboplatin and oxaliplatin play a key role, being administered in 
about 50% of anticancer regimens. Unfortunately, their use is hampered by severe 
side effects, production of drug resistance and poor pharmacokinetic activities. On 
the contrary, the Pt(IV) complexes are ideally suitable for such approach. They have 
octahedral geometry, so they are quite inert to substitution and reach intact cancer 
cells, minimizing the side effects and the off-target reactions. Moreover, the Pt(IV) 
complexes act as prodrugs, being activated by reduction within hypoxic cancer cells, 
releasing the corresponding Pt(II) complex and two axial ligands. These ligands can 
be biologically active molecules, providing an adjuvant or synergistic action with 
cytotoxic Pt(II) species, and ensuring the synchronous internalization of such Pt(IV) 
multifunctional drugs (“combo”). 
The biological properties of several newly designed, synthetized and characterized 
multi-action Pt(IV) prodrug candidates have been reported in this Ph.D. thesis.  
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Epigenetic agents, such as Histone DeAcetylase inhibitors (HDACi), seem to be 
suitable axial ligands. Indeed, a cisplatin-based Pt(IV) complexes containing the 
novel histone deacetylase inhibitor 2-(2-propynyl)octanoate (POA) as axial ligand 
was studied. Since POA has a chiral centre, also its isomers were tested, showed 
almost identical in vitro activity compared to the racemate. The POA-bearing Pt(IV) 
complex showed a marked in vitro antiproliferative activity on a panel of different 
human cancer lines and also a strong in vivo anticancer activity on Lewis lung 
carcinoma bearing mice, compared with the Pt(II) counterpart (i.e. cisplatin). 
Moreover, albeit having a single HDACi molecule, it exhibited in vitro and in vivo 
performances similar or even better to those offered by another Pt(IV) compound, 
featuring two HDACi (i.e VPA) molecules, with a more efficient biodistribution. 
These promising results have led to the investigation of the biological properties of 
a Pt(IV) derivate bearing the same POA molecule, but based on the oxaliplatin-
analogue cis-dichlorido(cyclohexane-1R,2R-diamine)platinum(II) (or 
[PtCl2(dach)]). The in vitro activity of the compound with racemic POA was 
evaluated on three human and one mouse colon cancer cell lines along with that of 
its isomers, and also in this case the IC50  and the cellular accumulation data showed 
that the activity of the three POA derivatives is almost identical. Moreover, the 
Pt(IV) complexes were one or two orders of magnitude more active than the 
references Pt(II) compounds cisplatin, oxaliplatin and [PtCl2(dach)], due to their high 
cellular accumulation. Finally, the dach-based Pt(IV) prodrug exerted also a marked 
in vivo anticancer activity on a pool of immunocompetent BALB/c mice bearing 
CT26 colon carcinoma. When orally administered the Pt(IV) prodrug inhibited the 
tumor growth more efficient than intravenously administered (i.v.) oxaliplatin. 
However, such a protocol is limited by the presence of heavy side effects, probably 
due to an extremely high Pt accumulation into the liver and spleen. Conversely, the 
performances of the Pt(IV) complex i.v. administered were much more promising in 
terms of tumor growth inhibition and persistence of the anticancer effects, along with 
lower nephro- and hepatotoxicity. Noteworthy, the dach-based Pt(IV) complex 
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containing one POA molecule, was able to induce immunogenic cell death, as 
demonstrated by the massive presence of the activated cytotoxic CD8+ T 
lymphocytes. Both metabolites [PtCl2(dach)] and POA, released upon intracellular 
reduction, seem to contribute to this process, leading to a reversion of the 
immunoescape mechanisms on colon cancer. 
Since this compound has shown a good efficacy against colon cancer, the in vitro 
antitumor activity of three couples of asymmetric Pt(IV) species, cisplatin- or dach-
based, containing the bioactive axial ligands clofibrate (2-(p-chlorophenoxy)-2-
methyl- propionic acid (CA) or heptanoate (HA) or octanoate (OA), was investigated 
on three different human colon cancer cell lines and on one ovarian cancer cell line. 
The two series of Pt(IV) prodrugs showed a marked anticancer activity, both on 
monolayer cell cultures and on 3D multicellular tumor spheroids (MCTS), compared 
to the Pt(II) counterparts. This potency is certainly due to a considerable 
accumulation in cancer cells of Pt(IV) prodrugs, bearing a lipophilic axial ligand (i.e 
CA, HA, OA); the dach carrier ligand itself significantly contributes to such an 
escalation of lipophilicity. Moreover, the dach-based series showed a higher 
selectivity towards colon cancer cells. 
Finally, inhibitors of cyclooxygenase (COX) enzymes, as Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs), have been suggested for chemoprevention on colon 
carcinoma, and cisplatin and several NSAIDs have proved to act additively or 
synergistically on several cancer cell lines. For these reasons the in vitro activity of 
two cisplatin-based Pt(IV) complexes containing an NSAIDs as axial ligand, (i.e. 
ketoprofen or naproxen) was evaluated. Both Pt(IV) complexes offered good 
antiproliferative performances on a panel of human cancer cell lines with different 
levels of COX-2 expression, including a malignant pleural mesothelioma one (a very 
chemoresistant tumor). The main reason of this increased activity, compared to the 
reference drug cisplatin, seems to be related to the enhanced lipophilicity of the 
Pt(IV) species (synergistic cellular accumulation). Indeed, their biological effects 
resulted almost independent from COX-2 expression, while these NSAID axial 
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ligands offered an additive contribution in the activation of the NSAIDs activated 
gene (NAG-1), involving in growth inhibition of cancer cells.  
In summary, as demonstrated in this Ph.D. work, an increase in antiproliferative 
activity of Pt(IV) prodrugs compared to their Pt(II) parent compounds is almost 
generally expected, as a consequence of the increased lipophilicity and consequently 
to the higher cellular accumulation, causing, in turn, proportionally higher DNA 
platination. An increase in lipophilicity can be achieved by using highly lipophilic 
amines as carrier ligands, as in the case of satraplatin, which entered in several 
clinical trials. This complex produces Pt(II) metabolites different from those usually 
employed in the clinic (i.e. cisplatin and oxaliplatin), also influencing the sensitivity 
towards different tumors. Alternatively, the addition of long-chain aliphatic 
carboxylic acids as axial ligands leads to an increase of lipophilicity in cisplatin- or 
oxaliplatin-based Pt(IV) compounds. The use of axial ligands with further biological 
properties,synergistic or additive with respect to those of the Pt(II) drugs, leads to 
these Pt(IV) multi-action complexes with promising pharmacological profile. These 
axial ligands are generally bioactive per se at concentrations higher than those of the 
Pt(II) metabolites. However, the synergistic cellular accumulation of the Pt(IV) 
prodrug allows a more efficient cellular accumulation causing an increase of the local 
concentration of the second drug (the axial ligand).  
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Thus, a multidisciplinary approach, involving inorganic chemists, biochemists and 
molecular biologists, is needed to understand the real advantages caused by the 
incorporation of such bioactive molecules in these combo prodrug candidates. 
For these reasons, future perspectives of this work could include a further, deeper 
investigation of the molecular mechanisms triggered in cells by the treatment with 
both cisplatin- and dach-based Pt(IV) prodrugs, containing the epigenetic agent POA 
as axial ligand. Indeed, among all the potential combos studied in this work, they 
showed the better in vitro and in vivo anticancer performances. Moreover, in this 
context, also other new Pt(IV) complexes, bearing different epigenetic drugs as axial 
ligand, could be designed, synthetized, characterized and investigated from a 
biological point of view. Particularly, in order to better understand the multi-action 
of these drugs, in vitro tests both on 2D monolayer cell cultures and on 3D MCTS, 
which resemble the features of in vivo tumor tissue and allow to study long-term 
effects of the drugs, will be performed. Importantly, also in vivo studies will be 
carried out, to understand how the route of administration can affect the antitumor 
efficacy and the side effects of these drugs. 
Finally, in order to better target the tumor tissue, a passive drug delivery strategy 
could be exploited. Thus, the biological properties of Pt(IV) complexes bound to 
several macromolecules or nanoparticles, including micelles and liposome, 
polymers, carbon nanotubes or other delivery systems could be investigated in detail.  
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